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Abstract
My first hypothesis in this thesis is that there is significant value vested in traditional
Chinese medicine that can be captured by converting them into ethical drugs through
scientific analysis, screening and validation. Further, holistic treatment is a key difference
between traditional Chinese medicine and western-type chemical drugs, which makes
Chinese medicine a very valuable category of knowledge. Using mixed formula is a
primary method of treatment in Chinese medicine. It is the application of distinctive
medical philosophies of Chinese herbal medicines in practices, reflecting the uniqueness
and advantages of Chinese medicine. For example, there are 96,592 mixed formula
recorded by "Dictionary of Chinese Medicine Mixed Formula" published in 1997. My
second hypothesis in this thesis is that value can be created and captured, under the
globalization context, from mixed herbal formulas for the mainstream world market with
the aid of fingerprint technologies.
To enter western markets as officially approved drugs through critical pathways, both
scientific and regulatory, Chinese herb drugs must demonstrate sound evidence for safety
and efficacy. I address in this thesis one of the central concerns of the pharmaceutical
companies and FDA, that is, how quality control and material consistency is assured and
how toxicity and drug kinetics of Chinese herbal medicines, either in its raw form, its
purified form, its composite extract form or its mixed formula form, may be measured
with reasonable scientific certainty and what would be the likely trajectory of further
research.
My thesis research involves the following aspects: firstly, I characterize, by and through
historical review and analysis, the formation of unique Chinese holistic medical
philosophy to apply herbal medicines, particularly mixed herbal formulas, to
systematically modulate the human body to prevent illnesses, to combat health problems
and to restore balanced health; secondly, I performed a comparative study on the
regulatory systems between Chinese SFDA and US FDA to provide insights on the trend
of harmonic convergence of laws and regulations and challenges going forward,
including collection and extrapolation of relevant statistical data; thirdly, I researched
emerging fingerprint technologies to address the central issues of standardization, quality
control, material consistency, safety and efficacy measurements of Chinese herbal
medicines; fourthly, I performed data collection on major Chinese sources of published
literatures and patent applications/grants for public and private medicinal knowledge
formation, which may be viewed as a surrogate indicator for embedded economic value
in the system, to compare trend and gaps between China and developed countries; and
lastly, I presented three case studies of development of an-diabetic drugs from herbal
sources, to illustrate how value may be created and captured through using modern
technologies to tap into the accumulative knowledge base in herbal medicine.
The thesis concludes that there are significant values to be captured, by and through
cross-border collaborations under the globalization context, from Chinese herbal
medicine. Both ethical single molecular entity (singleton) herb-derived drugs and mixed
formula herb-derived drugs may be created going forward.
1. Introduction
In this age of globalization, featured by free flow and optimized allocation of capital,
technology, information and service in the global context, economic interdependence and
interaction between countries are becoming stronger and stronger. Globalization can
bring many benefits, both tangible and intangible - ideas, reforms, goods, investments,
and even revolutions. China's participation in globalization is increasingly important to
the world. When the global economic growth remains weak in the past decades, China's
economy is one of the few bright spots. China has also provided the world with the
largest consumption market. When more than 1.3 billion people become well-off, the
incremental demand on everything will be enormous.
In the pharmaceutical industry, the trend of globalization and China's participation has
redefined the landscape and is bringing about new opportunities. On the one hand, the
Chinese pharmaceutical market is growing at an impressive double digit pace with a
projected value of $25 billion by 2008. 1 On another hand, Chinese medicine,
particularly herb-based medicine with a wealth of accumulated empirical effectiveness in
treating various illnesses, may become a new funnel of therapeutics. In this context, we
ask the question, can Chinese herbal medicine, which has helped Chinese people
maintain their health for thousands years, become an important value in the global drug
development in the pharmaceutical industry? Can it be an emerging source of new drug
development aiming at not only the Chinese ethnic market but the world market in both
developed and developing world? If the answer to this question is in the affirmative, what
are the means and ways to discover and realize this value?
My first hypothesis is that there is significant value vested in Chinese herbal medicine.
This statement, seemingly obvious, is undergoing a heated debate not only in China, but
also in the US and other developed markets. A high profile case, for example, is US
FDA's official ban of ephedra (an extract form of Chinese herb mahuang, which may
relieve cough and asthma, raise a person's energy and produce weight-loss) due to its
adverse effects in a small number of cases linking to heart attack, stroke and sudden death
because of its ability to raise blood pressure, increase heart rate and speed up brain
activity. To date, appeals have been filed in a vain effort to vacate such a ban, and most
interestingly, ephedra is still widely distributed and used by a significant number of users
in the US despite the FDA's official action. To address my hypothesis, the first set of
questions is to ask why an herbal product, such as mahuang, which has been used for
thousand years in Chinese medicine and proven to be effective in many applications,
would encounter such a severe regulatory penalty due to its toxicity effects. How are
toxicity and drug kinetics of Chinese medicine, either in its raw form, its composite
extract form, its mixed formula or its purified form, being measured? What are the
differences in the regulatory processes and standards, say, in the US FDA and Chinese
Summary of Advantages and Disadvantages of Increasing Pharmaceutical R&D Outsourcing to India and China, Frost
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SFDA? Is it possible to converge such systems to develop a universally accepted global
standard or technical standardization? Aside from differences in levels of technology, is
there anything intrinsically different in characterizing Chinese herbal medicine of
different compositions? The introduction part of the thesis attempts to answer the above
questions, so that the problem can be defined and a basic landscape can be laid out to
characterize the value or potential value of Chinese herbal medicine.
1.1 Accumulated Value in Chinese Herbal Medicine
1.1.1 Value accumulation in a long history
To appreciate the value and benefits of Chinese herbal medicine, we shall first review its
developmental trajectory. The purpose of this review is not simply for a layout of
significant historical events or landmark publications, rather, as the following narrative
will demonstrate, the intention is to illustrate a basic understanding of Chinese herbal
medicine, which has evolved over a long history from a herb-centric view by
characterizing the short-term therapeutic effects and side effects produced by various
herbs into an interactive view, where body and herbs are working together to combat
diseases and produce optimized health conditions in a time- and stage-sensitive manner;
and further into an integrated view, where herbal medicine is only one element of the total
multi-variant dynamic human-environment system, through which the human body
continuously modulates itself and responds to the external environment at the aid of the
herbal medicine. In this cognitive evolution about the relationships between the human
body, disease states and nature, the core understanding of traditional Chinese medicine is
one that any and all solutions to health problems are already vested in nature, because any
unhealthy and disease condition is essentially an internal imbalances that causes the
human body to become susceptible to diseases such as invasion of shanghan. By mixing
various natural products, particularly herbal medicines and other natural treatments such
as acupuncture and massage, the internal defense system and energy may be mobilized
and the internal system re-modulated. From modern cellular and molecular biology
perspective, perceivably, such yin-yang modulations induced by various herbal treatments
must have been intimately involved in the activation and regulation of multiple signaling
pathways and modulation of genetic circuitries that selectively express certain molecules
and proteins, which in turn produces desirable health outcomes.
This holistic view or systemic view in traditional Chinese medicine is fundamentally
different from what we term a scientific view, where the causal relationship between a
drug and response is largely linear, highly repeatable and predictable. The traditional
Chinese medical theory views the total human system in a much higher context; it
describes any and all health problems in a non-linear and continuously changing
perspective, it not only focuses on the relief of immediate symptoms, but also long-term
cultivation of the internal human defense system so that a balanced healthy state can be
restored and sustained. Using today's terminology, both the mixtures of herbal medicines
and the human hosts are working on a non-linear and systematic fashion - a concept that
often puzzles westerners. In recent years, systems biology developed very fast in western
scientific circles. From this new systematic perspective, the non-linear human systems is
reduced to many finite elements with quantitative and linear relationships, and such finite
elements, by and through collaborative synergies, produce a complex biological system.
This new scientific trend in the western world, quite amazingly, dubs seamlessly with the
philosophy and concepts in the core of traditional Chinese medicine. At the application
and practical levels, many treatments of diseases are becoming "systematic," instead of
single drug modalities, combinatorial drugs, analogous to Chinese herbal medicinal
mixtures at le:ast at the conceptual level, are increasingly being applied in clinical settings
to produce a more effective and sustainable therapeutic effect or with reduced side effects.
For example, the "cocktails" for HIV treatment, the combinatorial multi-drug treatments
for cancer and infectious diseases, just to name a few. Now, let's first look at its history.
Traditional Chinese medicine has a long history of 5000 years, dating back to the period
of the Huang Di (Yellow Emperor), the first Chinese emperor. In remote antiquity, when
struggling against nature, ancient Chinese people discovered some plant and food items
that had specific properties and could relieve or eliminate certain symptoms and diseases.
Then finding and using herbal medicine began together with many theories and methods
of practicing medicine, such as diagnostic methods of inspection, listening, smelling,
pulse-taking, and treatment methods of combining herbal remedies, acupuncture, cupping,
breathing exercise therapy, systematic exercise, hydrotherapy, etc. This knowledge has
accumulated generation after generation, including experiences, practice skills and
theories, which have great practical value but its scientific implications have been poorly
understood and are waiting to be further characterized.
%A1--
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Figure 1.1.1 History of China 2
Shen-nong.com is a website that provides information about the history of Chinese
medicine, referring to books and articles, such as A Brief History of Chinese Medicine
written by Peng Yoke Ho & F. P. Lisowski3. I summarize some important developments
in the following text and point out the value implications in these developments.
1.1.1.1 Han Dynasty (A) (206 B.C.-220 B.C.): Early classification according to herbal
toxicological properties - an herb-centric view
Among developments during Han Dynasty (206 B.C.-220B.C.) summarized by
Shen-nong.com, 4 an important book came out, named "Shennong Bencaojing" (Classic
of Herbal Medicine). The name of the author is not known.
2 http://www.shen-nong.com/eng/history/references.html
3 http://www.shen-nong.com/eng/history/references.html
4 http://www.shen-nong.com/eng/history/qinhan.html
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Figure 1.1.2 Shennong Bencaojing5
This landmark book is a comprehensive summary of 365 Chinese medicines, of which
252 originate from plant, 67 from animals, and 46 from minerals. It divides these
medicines into three categories based on their respective toxicological properties. The
first category has 120 medicines, they are non-toxic and have functionalities to preserve
vitality or extend life, such as the well-known ginseng (panax ginseng). The second
category consists of 120 medicines that can be used to treat illness and enhance a person's
health, but the herbs in this category, such as Chinese angelica (angelica sinensis) and
ephedra (mahuang), could sometimes be toxic and should be used carefully for certain
ailments. The third category includes 125 toxic medicines with side effects, and was
preserved for treating specific diseases. For example, the herb croton (croton tiglium)
may be prescribed to treat illnesses with edema or eliminate phlegm. This book may
represent the initial efforts in Chinese medical history to use accumulative empirical
evidences to characterize the herbal medicines according to their level of toxicity and side
effects, which has guided Chinese folk doctors for decades to carefully select and use
these medicines according to the intended purpose of prescription.
1.1.1.2 Han Dynasty (B) (206 B.C.-220 B.C.): Application of herbal treatments
according to disease processes - a host-centric view
Also during the Han Dynasty, several prominent physicians emerged 6 . The most famous
one is Zhang Zhongjing, who was respectfully addressed as "sage of medicine" and wrote
an important medical book, named "Shanghan Zabinglun" (Discourse on Fevers and
5 http://www.shen-nong.com/eng/history/qinhan.html
6 http://www.shen-nong.com/eng/history/qinhan.html
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Miscellaneous Illnesses), dealing with the treatments of many febrile conditions. Later in
the Song Dynasty (960A.D.-1279A.D.), this book was rewritten and divided into two
books called "Shanghanlun" (Treatise on Febrile Diseases) and "Jinkui Yaolue"
(Summary from the Golden Chest). The significant effect of doctors in this time and their
publications is the layout of foundation of Chinese medicinal philosophy, which views
the disease conditions and symptoms as time series events and herbal treatments must be
dynamically adjusted according to the host's illnesses at different stages of a disease
process - marking the initial formation of interactive medicine.
Figure 1.1.3 Shanghan Zabinglun7
1.1.1.3 Tang Dynasty (618-907 A.D.): Integration of pharmacy, clinical medicine and
education - formation of philosophy of individualized medicine
From the information provided on shen-nong.com, we can find that during the Tang
Dynasty (618-907 A.D.), an Imperial Academy of Medicine was founded and run by the
government to serve the emperor, his family and nobles. This academy had two divisions,
a clinical doctors division and a pharmacy division. The pharmacy division helped
maintain the Imperial Academy's herb plantation and focused on the standardization of
herb processing. This academy is also a medical education institution with lectures and
apprenticeship. If a student failed the final examination required for graduation, he would
be dismissed from the academy. Doctors were promoted based on their treatment success
7 http://www.shen-nong.com/eng/history/qinhan.html
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rate, a system that measures the outcome of the treatments rather than standardizing the
treatment methodology or herbal formulation, which were highly variable subject to the
specifics of the target disease process and patients. Herbal King Sun Simiao in the Tang
Dynasty is one of the most influential physicians in the history of Chinese medicine,
famous by his application of medicine and his adherence to an ethical code. His best
known works are "Qianjin Yaofang" (Prescriptions Worth a Thousand Gold for
Emergencies or Precious Prescriptions for Emergencies) and "Qianjin Yifang"
(Supplement to the Essential Prescriptions Worth a Thousand Gold or Supplement to
Precious Prescriptions). The first set is comprised of 30 volumes and lists 5,300
prescriptions. The second set is also made up of 30 volumes and lists 2,571
prescriptions. When woodblock printing was improved by Bi Sheng in 1040 A.D. with
the invention of movable type, many medical classics were rewritten and many medical
texts were published under government supervision or individually.
During the above period, the herbal medicine was not an independent discipline, but
became integrated with clinical practice and medical education. The medical practice and
herbal medicine was more of an art than science, because the proliferation of
combinatorial herbal treatment formulas and many of the formulations of various herbs
were highly individualized according to the basic patient parameters such as age and
previous health conditions, disease processes and stages, and sometimes according to
individual doctor's preferences and accumulative experience.
1.1.1.4 Song Dynasty (960-1279 AD): Chinese herbal pharmacopoeias - efforts to
standardize herbal formulations
The Song Dynasty (960-1279 AD) witnessed scholarly compilation of many
pharmacopoeial texts. The following is a summary of important pharmacopoeial texts in
the Song Dynasty (960-1279 AD)9
Date Author, Title of Pharmacopoeias Comments
973 Ma Zhi with Kaibao Bencao (Herbal Medicine of This herbal text expanded the number of drugs
others the Kaibao Era) to 983 and modified their classification.
1057 Su Song and Jiayou Buzhu Bencao (Complete and The number of drugs was increased to 1,083.
colleagues Annotated Materia Medica of the
Jiayou Era)
1061 Su Song and Tujing Bencao (Illustrated Materia This was the first time illustrations were
colleagues Medica) included in a pharmacopoeia.
1108 Tang Zhenglei Bencao (Classified Materia A unique pharmacopoeia listing 1,558 drugs
Shenwei Medica) with illustrations; it remained the model for the
next 500 years.
1116 Kou Yanyi Bencao (Development of This book clarified the properties and
Zongshi Herbal Medicine) pharmacology of herbs.
8 http://www.shen-nong.com/eng/history/suitang.html
9 http://www.shen-nong.com/eng/history/five.html
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Besides pharmacopoeias, many prescription books were also published. "Taiping
Shenghuifang" (Prescriptions from the Pharmacy of Harmonious Assistance),
commissioned by the government and written by Wang Huaiyin at the end of the tenth
century, listed a total of 16,834 prescriptions and gave details of the prescription, herbs
(drugs) used, syndromes and pathology. The following are some important prescription
texts in the Song Dynasty (960-1279 AD)10:
Date Author Title of Prescription Book Comments
1107 Chen Shiwen Taiping Huimin Hejijufang This book lists 788 prescriptions and gives
-1110 and Pei (Prescriptions from the information on how to prepare and use drugs. It
Zongyuan Pharmacy of Harmonious represents the first government-published
Assistance) prescription book in the world.
1111 Cao Shengji Zonglu, (General This book lists 20,000 prescriptions and
-1117 Zongxiao and Catalogue of Divine describes the causes, symptoms and cures for
other medical Assistance) different illnesses.
officers
1253 Yan Yonghe Jishenfang, (Prescriptions for This was an individually published text. The
Saving Life) decoction known as gui pi tang is still used
today.
The relevance of the above pharmacopoeias and prescription texts to this thesis is that
most of the herbal drugs were in raw form with limited processing or treatments in these
pharmacopoeias and prescriptions were in composite formulas rather than as single herbs,
which is substantially different from western style pharmacopoeias that increasingly
characterize the drugs' properties, effectiveness and side effects in their stand-alone
applications. Additionally, the formulations of the 20,000+ herbal prescriptions are by far
not exclusive, rather, the prescriptions were meant to represent only the "core" formulas
and the doctors were always at the liberty to change or adjust the composition and
quantities of the herbs according to the host conditions and disease processes or stages.
Further, the treatments were always on an experimental mode, in the sense that each
prescription would always be based on the host responses to previous "trial" treatments -
a real option time series proposition, if I were to use a modern concept to describe the
continuously information-capturing, learning and actions.
The core idea underlying the above Chinese herbal treatments is derived from the
philosophy that any unhealthy state is an imbalance of bodily yin and yang, and illnesses
and symptoms are only the superficial manifestation of internal imbalances. The purpose
of the treatments is not only to relieve the symptoms, but more importantly, to eliminate
the root causes. It is also important to appreciate that many Chinese herbs, used
singularly or in composite formulas, are meant to mobilize the human defense system
such as "qi" (energy) and "xie" (blood), and through such mobilization, the human body
will build necessary "troops" to combat the illnesses. Using today's scientific concepts,
the input of herbal treatments do not necessarily proximately cause the treatment outcome
10 http://www.shen-nong.com/eng/history/five.html
in the short run, at least not in a very linear fashion, because the herbs could only work
through the complex human mechanism, which is not only different from person to
person, but allso its internal pathways and mechanisms are very difficult to delineate. To
further illustrate this point, for example, modern medical scientists have discovered that
none of the individual herbal components in some very effective anti-febrile herbal
formulas have anti-bacterial effects from controlled in vitro experiments, nonetheless the
formulas could effectively combat pneumonia caused by bacteria. As I will illustrate
further in this thesis, even in cases that a single herb may be very effective in treating a
certain medical condition, but when we use current scientific deductive methods to
analyze the effective chemical components, we are often puzzled by the findings. For
example, we are currently analyzing an herb in China's Yunnan Province, which has long
been commercialized as QianLieAn to be effective in treating non-bacterial prostatitis.
We have narrowed it down to 7 chemical compounds, among which three have shown
limited but weak effects and the remaining four are not effective at all regardless of
dosage when used singularly. But when we combine all 7 compounds together, however,
the composite drug works wonders (author's private research data). We instantly realize
that the synergies created among and between these individually ineffective components
may be the true direction of the pharmacological development going forward. We must
not only use deductive methods as science has advanced, but more importantly, use
inductive methods to navigate the complex world of combinatorial pharmacology, a road
less traveled but most promising.
1.1.1.5 Song and Ming Dynasties (960-1644 A.D): Acupuncture, surgeries,
meditation, qigong and herbs - formation of holistic medicine
During this period many different medical theories and schools, as well as treatment
modalities became more mature. The various ideas further converged into a fundamental
understanding that internal and external treatment should be combined to preserve health
and treat illnesses. The developments during the Ming Dynasty include methods for
achieving analgesia, aseptic techniques and homeostasis contributed to various surgical
treatments. Among these new Chinese medical technologies, acupuncture, was also
advanced during this period. Two life-size male bronze statues were cast, complemented
by a book called "Tongren Shuxue Zhen Jiu Tujing" (Illustrated Manual of the Bronze
Man Showing Acupuncture and Moxibustion Points). These statues had 657 acupuncture
points drilled into them which were filled with water and covered with wax. When a
student needled the acupuncture point correctly, water would leak out.
The book "W2ike Zhengzong" (The Genuine Surgery), written by Chen Shigong, covered
a series of surgically treatable diseases and many effective prescriptions. The book
outlined the surgical procedure for the repair of a "slashed throat," the use of copper wire
to excise nasal polyps under local anesthesia, and described in detail cancer of the lip and
breast. These were the earliest surgical records in the history of traditional Chinese
medicine.
Figure 1.1.4 Waike Zhengzong"
With regard to the herbal medicine, another landmark book was written by a very
productive writer and seasoned medical practitioner Li Shizhen. The book was called
"Bencao Gangmu" (Compendium of Material Medical), which is one of the most
comprehensive and highly regarded Chinese medical texts. The book summarizes most
available information about herbal medicine in the sixteenth century. Li added 374 new
medicines (mostly herbs) in his text in a list of previously known 1,892 medicines and
included over 1,000 illustrations. Classification of medicines in the "Bencao Gangmu"
differed from previous pharmacopoeias in that he developed 16 headings: 1-water, 2-fire,
3-earth, 4-metal, 5-stone, 6-plant, 7-grain, 8-vegetable, 9-fruit, 10-tree, 11-products
derived from garments and tools, 12-insect creatures with scales (reptiles, fish),
13-creatures with shells, 14-bird, 15-quadruped, and 16-products of human origin. This
book was supplemented by another book called "Bencao Gangmu Shiyi" in the Qing
Dynasty. The fascination for ancient classics re-emerged during the Qing period and
many were re-edited, such as the "Huangdi Neijing" (The Yellow Emperor's Medicine
Classic), "Shanghanlun" (Treatise on Febrile Diseases) and "Jinkui Yaolue" (Summary of
the Golden Chest). 12
These medical publications formed a very comprehensive body of medical knowledge
that were referred to and supplemented by medical practitioners. The medical
practitioners usually combine herbal formulas with all other available technologies such
as acupuncture, qigong and surgeries to treat the patient in a holistic fashion. Overall, this
represents the formation of holistic medical theory and practice.
Since the beginning of the 19th century, however, with western medicine entering and
developing rapidly in China, traditional Chinese medicine's development was affected
severely, even considered as unscientific and feudal after the Opium Wars. After the
foundation of the People's Republic of China, the government affirmed the policy to
1 http://www.shen-nong.com/eng/history/ming.html
12 http://www.shern-nong.com/eng/history/ming.html
-10-
protect traditional Chinese medicine, but for a long period of time, the schools of
traditional Chinese medicine and the western medicine were separated into different
camps. Traditional Chinese hospitals were so named and herbal medicines were the
primary treatment modalities. The western hospitals dispensed pills and practiced
surgeries as the primary treatments.
From empirical perspective, over the past thousands of years, traditional Chinese
medicine, by and through consistent practice, learning, research and scholarly summation,
has developed a set of both practical and balanced health care system, which is affordable,
safe, efficacious and effective. Herbal medicine is viewed as a central and integral
element of this system.
1.1.2 Unique medical philosophy
If Chinese herbal medicine, over thousands of years, produced positive health benefits,
helped combat many grand epidemics and other natural health hazards, and eventually
preserved and sustained the largest population on earth, why can't we simply use the
modem technology to dissect the proven herbs or herbal formularies and find the most
effective compounds in these herbs, herbal powders or composites? In other words, if the
value is empirically obvious, why couldn't we easily capture it? The answer to this
question is central to this thesis.
In the past centuries, particularly in the past decades, many researchers and scientists
have attempted to utilize the latest technologies to screen, isolate and purify molecules
and compounds from herbs and indeed have achieved compelling successes. If we go
through western pharmacopoeias, we could identify plentiful drugs that are traceable one
way or another herbal origin, from drug for congestive heart failure digoxin to the
wonderful anti-cancer drug taxol, to the three cases that I would present later in this thesis.
But many efforts along these research paths or most of the efforts in fact, are fruitless,
particularly in recent years, despite the availability of modern chemical technologies in
isolating and fast-screening chemical compounds. There are a few hypotheses we could
postulate, for example, first, the low-hanging fruits are already taken; second, the extract
from the plant is no longer necessary because the recombinatorial chemistry can basically
reconstruct from many known compounds. My hypothesis, to partially explain this
phenomenon of reduced productivity in using reductive scientific research to develop
herb-based drugs, is that many of the herbal medicines must retain their composite
formula in order to maintain clinical efficacy and effectiveness. In other words, I believe
that the conventional single molecule screening approach through identifying single
herb-derived compounds is one method to capture the value in herbal medicine, but by far
not the only "scientific" method. Characterizing composite herbal compounds or mixtures
through fingerprint related technology opens a new avenue to extracting the value in
herbal products. Such methods may be cheaper, faster and may result in affordable and
effective medicine for preventing and treating illnesses, and potentially improve quality
of life and prolong productive life.
This seems to be a bold hypothesis because it deviates from conventional scientific
wisdom. This wisdom requires finding a chemical entity that is minimally required to
produce a therapeutic effect(s). One may argue that putting a bunch of mixed compounds
which are not well characterized individually and make a collective pharmaceutical claim,
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is simply unscientific.
To address the viability of the hypothesis and start to answer these scientific concerns,
let's review the Chinese philosophies relevant to traditional Chinese medicine in general
and to herbal medicine in particular. With a basic understanding of these philosophies, I
hope we can establish some common concepts and communicative language.
During the long Chinese history, Chinese medicine created and consummated some
unique medical philosophies, including the concepts of organic one, wuxing (five
evolutions or elements), qi, and yin-yang, as well as the use of mixed formula.
1.1.2.1 Organic one - systematic and holistic philosophy
As stated in the early part of this thesis, the Chinese organic one concept is fundamentally
similar to the philosophy underlying the present day systems biology. The concept of
organic one is the central tenet of Chinese medical theories, which views the body as a
unified system of connections that, once stimulated, can help other parts of the body to
maintain health. This is a concept of holism. Holism is a key difference between
traditional Chinese medicine and western modern medicine, which makes Chinese
medicine a very valuable category of knowledge. As stated earlier in this thesis, the
Chinese organic one concept is fundamentally similar to the philosophy underlying the
present day systems biology, which is still under fast development, thanks to the modem
computing technologies and advanced algorithms.
1.1.2.2 Yin-yang - philosophy of balance
Theory of yin-yang was used by ancient Chinese people to explain the observed
phenomena in nature. The theory is based on two basic components: yin and yang, which
combine in a complementary manner and form a method for explaining relationships
between objects. Gradually, this logic was developed into a system of thought that was
applied to other areas, such as medical practices.
Figure 1.1.5 Symbol of yin-yang13
Usually, yang is associated with energetic qualities; while on the other hand, yin is
associated with the physical form of an object and has less energetic qualities.
13 http://www.shen-nong.com/eng/principles/whatyinyang.html
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The properties of yin and yang include: (1) yin and yang oppose each other while
mutually controlling and inhibiting each other at the same time, resulting in a continuous
state of dynamic balance; (2) yin and yang mutually create and depend on each other, the
activity (yang) of the body is nourished by its physical form (yin) and the physical form is
created and maintained by the body's activity so as to achieve a balanced state of health;
(3) yin and yang change and grow in a cyclic and balanced manner; (4) yin and yang can
transform into each other when one aspect goes to an extreme. 14
According to the yin-yang theory, the body's organs and tissues can be classified to yin
and yang based on their functions and locations. "The upper body belongs to yang while
the lower body belongs to yin. Other yin yang pairs in the body include the interior (yin)
versus the exterior (yang), the front (yin) versus the back (yang), the inside (yin) versus
the outside (yang) of the limbs and the five yin organs versus the six yang organs. Each
organ can also be further divided into yin and yang aspects such as heart yin and heart
yang and kidney yin and kidney yang.""15 Health is achieved when yin and yang are in
harmony and yin yang disharmony is the cause of disease and physiological disorders.
Patients were diagnosed according to their disharmony pattern. There are eight principal
disharmony patterns as shown on the following table'6 .
Disharmony Yin/Yang Manifestations
Pattern
1 Interior Yin An interior pattern is generated by internal disharmony such as a
disorder of organ function.
2 Exterior Yang An exterior pattern is generated by "external influences" such as wind
and cold (i.e. common cold).
3 Cold Yin A cold pattern is manifested by signs such as a pale face, cold limbs,
aversion to cold, clear urine, or watery stools. The signs are usually
related to non-excitatory physiological functions.
4 Heat Yang A heat pattern is manifested by signs of a red face, high fever, dislike
of heat, dark urine, or constipation. The signs are usually related to
excitatory physiological functions.
5 Deficiency Yin Signs of frail and weak movements, tiredness, and shortness of breath,
low voice, or dizziness indicate a deficiency pattern. The signs are
usually related to lack of energy of normal functions.
6 Excess Yang An excess pattern exhibits signs of heavy movements, heavy and coarse
respiration, or discomfort when touched with pressure. The signs are
usually related to an excess/accumulation of evils/metabolic waste.
7 Yin Yin General pattern groups for yin manifestations include interior, cold and
deficiency patterns.
8 Yang Yang General pattern groups for yang manifestations include exterior, heat
and excess patterns.
14 http://www.shen-nong.com/eng/principles/propertiesyinyang.html
15 http://www.shen-nong.com/eng/principles/applicationlyinyang.html#1
16 http://www.shen-nong.com/eng/principles/applicationlyinyang.html#1
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Herbs also contain yin and yang properties and taste differently. Cold and cool nature
herbs belong to yin while hot and warm herbs belong to yang. Yin herbs taste sour, bitter
and salty, and yang herbs taste sweet and pungent. In formulating a treatment, correct
herbs must be identified to adjust the disharmony pattern in the patient and thus help
maintain the body's balance and health. It is essential to understand that both yin and yang
properties coexistence in anything, inside human body, inside an herb, side an herbal
formula, etc. Such a seemingly paradoxical thinking is often confusing to a person trained
in western ways of logical thinking, but is so fundamental to traditional Chinese
medicine.
1.1.2.3 Wuxing
To interpret their observations of the natural world, ancient Chinese people developed the
theory of wuxing, after the theory of yin-yang. This theory asserts that substances can be
divided into five basic elements: wood, fire, water, metal and earth, each containing
unique characteristics and properties. Ancient medical practitioners used this theory in
medical practices, viewing these five elements corresponding to different aspects of the
natural world and the body as follows:"
Wood Fire Earth Metal Water
Orientation East South Middle West North
Season Spring Summer Late Summer Autumn Winter
Climate Wind Summer Heat Dampness Dryness Cold
Cultivation Germinate Grow Transform Reap Store
Yin Organ Liver Heart Spleen Lung Kidney
Yang Organ Gall Bladder Small Intestine Stomach Large Intestine Bladder
Orifice Eye Tongue Mouth Nose Ear
Tissues Tendons Vessels Muscles Skin & Hair Bones
Emotions Anger Joy Pensiveness Grief Fear
Color Blue/ Green Red Yellow White Black
Taste Sour Bitter Sweet Pungent Salty
Voice Shout Laugh Sing Cry Groan
Dual modulation exists among five elements and organs belonging to different elements.
17 http://www.shen-nong.com/eng/principles/whatfiveelements.html
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Figure 1.1.6 Dual modulation exists among five elements and organs
The relationships of the five elements play an important role in maintaining a balanced
lifestyle. A simple illustration considering season changes is as following. "During the
spring season, which belongs to the wood element, we should avoid excessive anger in
order to stay healthy. In the winter season, which belongs to the water element, our
bodies prefer to store energy so rest is important. Storage is an important function of the
water element; therefore, in winter it is advisable for people to go to bed early. Even
today, the application of the five elements theory remains relevant in promoting health.
Understanding the relationships between the elements is the first step to achieve a
harmonious balance in nature and life." •8 The above statement would for sure sound like
complete nonsense to a western reader, because anyone with rudimental scientific
training or basic understanding of human anatomy would not believe this theory for a
split second. But once the theory is applied together with traditional Chinese medicine, it
works quite well. The five elements, human organs and yin-yang are not physical
materials, but symbols of invisible mechanics that regulate human being's life processes.
1.1.2.4 Qi
In traditional Chinese medicine, qi, blood and body fluids are the most important
fundamental substances. Qi is the life energy or life force flowing within the body. It
refers to the physiological functions of organs and meridians. Qi in the human body
comes from itwo main sources. The first is inherited from our parents at conception,
known as the "innate vital substance." The second source is derived from essential
substances in nature such as the air we breathe, food and water. Both the inherited and the
acquired vital energies are further processed and transformed by the organs.
18 http://www.shen-nong.com/eng/principles/applicationfiveelements.html
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There are four types of qi: inborn qi, pectoral qi, nutritive qi and protective qi. For
example, the pectoral qi protects against evils, like the immune system which helps
prevent disease from occurring or spreading. It moves outside the blood vessels and
circulates in different areas from nutritive qi. Internally, it will be distributed to the
diaphragm and scattered around the chest and abdominal cavities. Externally, it moves
between the skin and muscles providing protection. Protective qi not only guards against
illness and <disease, but also regulates the sweat glands and pores and provides
nourishment for the skin, hair and muscles.'19
Cultivating, preserving and streamlining the qi is central to the host-centric medical
theory and also one of the reasons why the same herbal formula would produce different
results on different hosts and why the same disease in different hosts would require
different herbal formulas. Once the conditions of the host qi are introduced as an
additional set of decision variables, the herbal formula becomes highly customized
according to each person's specific situations. This is why, thousands of years ago,
Chinese medicine already laid out the principles of individualized medicine as we know
today.
1.1.2.5 Mixed herbal formulas - an untapped value for the world drug market and a
new hypothesis
Using mixed formula is a primary method of treatment in Chinese medicine. It is the
application of the unique medical philosophies of Chinese medicine in practices,
reflecting the uniqueness and advantages of Chinese medicine. Diseases are complex, so
single ingredients have trouble achieving good efficacy, while two or more ingredients
mixed together through certain processes can produced much better effects. In the long
history of fighting various diseases, Chinese physicians found that some herbal medicines
would produce unusual actions when mixed, leading to enhanced efficacy, reduced
toxicity, or efficacy for other diseases. Accumulation of such findings led to knowledge
of different matching formulas among certain herbal medicines. When Chinese
physicians treated patients, they designed formulas according to a theory of balancing
effects of efficacy, support, safety and induction for other treatments. The formula was
created not only for the control of symptoms but also for a transition or restoration to a
desirable healthy state. Thousands of mixed formula were developed and validated as
effective during thousands of medical practices in China. For example, there are 96,592
mixed formula recorded by "Dictionary of Chinese Medicine Mixed Formula" published
in 1997. In the face of wide availability of western-style drugs that consistently produce
predictable efficacies, many mixed herbal formulas still are used in today's treatments in
China, particularly for many hard-to-treat diseases and chronic health problems, an
evidence of their efficacy.
Summarizing the above, we derive a new hypothesis: there must be values to be created
and captured through understanding and commercializing these proven formulas. Such a
new value-creation system is alternative and in addition to the current analytical
methodology to narrow down to a single chemical compound, which has been known to
19 http://www.shen-nong.com/eng/principles/qi.html
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be a most expensive and lengthy process and the success rate is diminishing. The answer
appears to be a no-brainer, but the question is how? How do we characterize these
formulas without understanding exactly what chemical ingredients are contained in them?
How do we to standardize the processes and measurements so that each batch of such
formulas is consistent? How can we be assured that these products would fulfill the
regulatory requirements for safety and efficacy? Let's move on from here.
1.2 Current Value Utilization Efforts by Global and Chinese
Pharmaceutical Companies
With the drying up of the new drug development pipelines and inspired by many
successful stories in discovering new drug-like compounds from Chinese herbs, the
perceived value of Chinese medicine is attracting more and more attention in the world.
Major pharmaceutical companies such as Hoffmann La Roche, GlaxoSmithKline, Eli
Lilly, Novartis and Pfizer have established joint ventures and wholly owned subsidiaries
in China. For example, Novartis has established six join-venture companies or projects in
China and employs over 1,700 employees. Novartis also trains Chinese researchers in
Switzerland. Novartis is establishing itself in pharmaceutical development. It is also
bringing in experts from Europe to China to establish clinical trial centers in Chinese
hospitals, which will allow the company to perform clinical trials in China. Novartis has
recently invested $100 Million and established its first R&D center in China, which is the
sixth worldwide. It is also experiencing a sales growth of 25.0 percent annually in
China.20
At the same time, Chinese pharmaceutical companies also began to seek financing in
international financial markets, pursue mergers and acquisitions, form partnerships with
global pharmaceutical companies, and apply for drug approval in other regulatory
schemes. For example, a Chinese herbal medicine company named Tongjitang Chinese
Medicine Company has successfully completed its initial public offering on the NYSE.21
In this globalized value utilization process, there is a bridge opportunity. On the one side,
western pharmaceutical companies face increasing drug innovation gap and cost
escalation pressure to develop new drugs, with their irreversible sunk investments in
advanced drug development technologies, instruments and other capital assets.
20 Summary of Advantages and Disadvantages of Increasing Pharmaceutical R&D Outsourcing to India and China, Frost
& Sullivan research report, July 22, 2005
21 http://retailroadshow.com/
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Figure 1.2.2 Widening pharmaceutical innovation gap23
On the other side, many Chinese pharmaceutical companies have accumulated significant
knowledge about Chinese medicine with a long period of practical usage as well as
22 Summary of Advantages and Disadvantages of Increasing Pharmaceutical R&D Outsourcing to India and China, Frost
& Sullivan research report, July 22, 2005
23 Prescription for Progress: The Critical Path To Drug Development, Robert Goldberg, Ph.D. and Peter Pitts, A Working
Paper of the 21st century FDA Task Force, June 2006
- 18-
1I · · · · ·L J J • • 3 • • J
d~' " a"a~ " BBe c',d ,$) ~P AVP~
academic and industrial researches. They have lower R&D costs relative to their western
counterparts, and a large pool of research talents who understand western technology and
skills. But this knowledge base, this pool of qualified researchers and intermediate
products has apparently been undercapitalized or underutilized. Very limited Chinese
herbal drugs are sold in the western mainstream markets and a very small number of
herb-derived drugs have made their ways through the US regulatory system as officially
approved drugs. This following figure is a simplified illustration for the potential bridge
opportunity, which, under the current globalization trend and cross-border collaborations,
may unleash the hidden values in Chinese herbal medicine.
"Bridging"
* Advanced Opportunities * Needs advanced
technology technology: "late
* Needs low-cost
drug development
solutions
* Largest market in
value
* FDA compliant
drugs
* Mature market;
strong competition
starter" in biotech
* Low drug development
cost
* Current market small
* Drugs generally not FDA
compliant
* High market growth
potential: expected to
become top 5 by 2020
* Unique herbal medicine
Figure 1.2.3 Bridging opportunity between western world and China
1.3 Efforts to Modernize Chinese Herbal Medicine
To enter western market as officially approved drugs, Chinese herbal medicines must
demonstrate scientifically sound evidence for safety and effectiveness, as well as
chemical properties and mechanisms. The fast advancements in the analytical and
biological sciences, along with innovations in genomics and proteomics provide powerful
tools to validate such medicines. This is a well established developmental pathway for
Chinese herbal medicine and is being practiced by most international pharmaceutical
companies. I call it the singleton drug development pathway. There is potentially another
herb-derived .drug development pathway for the world mainstream market; I tentatively
name it the alternative pathway in hypothesis for this thesis, or mixed formula herb drug
development pathway. Let me describe the concepts first.
1.3.1 Singleton drug development pathway
The most commonly followed developmental trajectory, or rather, a logical thought
process, is to look for efficacy leads from empirical clinical evidence or laboratory
evidence of various individual Chinese herbs and use these leads as the starting point for
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new drug development. The purpose of this pathway is to screen, by various extracting,
isolating and purification technologies, the effective molecules that may meet safety and
efficacy requirements in IND or NDA regulatory processes. Once a drug is approved, the
drug may be marketed in the US and/or in the world.
Among the first compounds derived from Chinese herbs to enter the Western
pharmacopoeia was ephedrine, an amphetamine-like stimulant, firstly isolated by a
Japanese researcher in late 19th century from the Chinese medicinal herb mahuang
(ephedra sinica), which was used to treat congestion. It is a common ingredient in
over-the-counter decongestants and prescription medications for bronchial asthma,
among other products. Mahuang is also used in nonprescription dieting aids, and as a
legal way to get high, dubbed "herbal ecstasy." But an increasing number of reports of
adverse effects have prompted several countries to ban nonprescription uses; such
countries include the United States.
The recent significant drug derived from a Chinese medicinal herb is a compound called
artemisinin from herb qinghao, or artemisia annua, a relative of the sweet wormwood
found in North America. The traditional texts identified qinghao as beneficial for treating
fever; the researchers found that artemisinin killed even chloroquine-resistant strains of
plasmodium, the parasite that causes malaria. Recent work in US and European labs
suggests that artemisinin may also have anticancer properties. Novartis eventually joined
forces with Chinese partners and patented the compound and received FDA approval.
Although artemisinin has delivered great value to humankind, the original Chinese
researchers earned almost nothing. Zhou Weishan, a chemist at the Shanghai Institute of
Organic Chemistry who led the efforts to synthesize artemisinin, says they "never
patented any part of the work." 24
Later in this thesis, with some detail I will use three real world examples to delineate how
herbs/plants have been developed or are being developed into FDA-approvable singleton
drugs. These three examples, hopefully, will shed some light for drug development
companies on how knowledge is accumulated, opportunities sensed and captured, and
value created through modern chemical and molecular technologies. The first example,
metformin, is a successful example of plant-derived singleton drugs for diabetes that has
received FDA approval. The second example is an on-going research on herb
banaba-derived PGG and its derivatives, which has undergone decades of purification
and validation, and is now targeting the diabetic market. The third example is the
compound resveratrol, originally derived from grape skin, is being developed into a
fast-track diabetic drug.
1.3.2 Mixed formula development pathway
One of the central themes of this thesis is to argue, as laid out in the previous pages, that
much of the value of traditional Chinese medicine is embedded in the mixed formulas it
has accumulcated over thousands of years and validated continuously through clinical
applications. These formulas were developed and built up according to the unique
24 The New Face of Traditional Chinese Medicine, SCIENCE , 10 January 2003 Vol. 299 pp 188-190 .
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Chinese philosophy of treating the illnesses to provide long-term and holistic/systematic
solutions to optimize the total health condition, prevent illnesses from coming back and
restore the human body's internal equilibrium/balance, rather than focusing on the
symptoms which are only manifestations of the disease processed or targeting organs in a
narrowly defined context, as most western medical theories often so define them. As such,
this thesis emphasizes the method of modernizing Chinese herbal medicine by using
modern scientific methods to analyze and validate Chinese herbal medicine mixed
formulas, optimize the formula to improve efficacy and reduce side-effects, and
manufacture under modern and strict quality management systems.
The above concept is based on compatibility theory in traditional Chinese medicine.
Compatibility theory of mixed formula is developed in accordance with the theory of
different natures of herbal medicine and the theories about the mechanisms of human
defense system under different diseases. This is the foundation of using composite
ingredients in disease treatments to realize various efficacies or to improve efficacies
when combined with other treatments. Compatibility theory of mixed formula is a theory
about the differences in biologic effects when changing the mixture of various ingredients,
reflecting the organic mixture of effective components of different herbal medicines and
the collaborative synergies among and between different activated pathways, processes or
targets, although at the moment such complex molecular mechanisms are less well
understood. Further, compatibility theory is not about simple mixing of different
ingredients, but about the integrative formulation involving primary herbs and other
associated herbal ingredients that exercise effects of synergistic efficacy enhancement,
toxicity reduction, and host health modulation. If analyzed with modern chemical
technologies, these effects may result from changes in chemical characteristics and
biologic effects of one or more ingredients after mixing, or effects on multiple targets and
multiple action processes after mixing. Efficacy of mixed formula may derive from direct
action on receptors, but more effects may derive from the changes in the chemical
environments caused by the mixed formula, which then act on receptors or other biologic
processes.
There have been extensive published articles, particularly in Chinese journals, about
using various modern technologies and methods to understand the mixed formulas.
Summarily, some of the modernization researches of mixed formulas focus on how to use
modern chemical and biological theories and technologies to analyze the isolated and
combinatorial constituents of effective mixed formulas and to understand the
characteristics of different biological targets or markers in experimental animal and in
actual patients after treatment with mixed formulas, in an effort to correlate the symptoms
and disease pathology with the mixed formulas. In this research area, apparently, using
system biology research methods may be better suited than the reductive scientific
research methods when analyzing mixed formula of Chinese medicine because of the
systematic and holistic philosophy underlying the Chinese medicine, while chemical
analysis of each ingredient of mixed formula may act as the starting point to analyze the
whole formula. Once the efficacy and safety can be validated, researches may further
optimize the mixed formula to understand how variances in ingredients or the amounts of
different ingredients and different mixing methods would affect the efficacy or safety
profiles of the formula. For example, Monte Carlo analysis may be applied to randomly
selected samples. Scientific analysis methods can be used to understand the effective
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components, the chemical characteristics of the effective components, and the
relationship of each ingredient to the efficacy. Modern extracting technology, such as
solvent extraction technology, solid-phase extraction technology, reversed-phase
chromatography, membrane separation, and supercritical extraction technology, can be
applied to validate the effective portion of mixed formula. In short, as generations of
Chinese doctors have experienced and repeatedly illustrated, special synergistic effects
will emerge when mixing various ingredients of a mixed formula, such effect may
include coordination, efficacy enhancement, toxicity reduction, and so on. So drugs
developed from modernized mixed formula may have unexpected good results with
respect to issues of safety and efficacy, the central concerns surrounding any medication
agents.
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2. Critical Paths to Value Realization
Creating and capturing value in Chinese herbal medicine involves success in various
areas and alignment of various necessary elements, which, altogether, form the critical
paths. Understanding the major elements and defining characteristics of each would help
us understand the space and platform of operations, for example, the limitations and
restrictions imposed by the legal and regulatory systems. In the following pages, this
thesis provides a comparative perspective of the history, operating principles, structures,
processes, rules and regulations of the United States Food and Drug Administration
(FDA), and the Chinese State Food and Drug Administration (SFDA) that are important
and relevant to the theme of this thesis, to provide a sketch of the harmonic efforts in
converging the regulatory systems, the point of divergence and the challenges.
Understanding and comparing the two regulatory systems provides an important
knowledge base in constructing a practical and feasible critical path(s) in creating and
realizing the value in Chinese herbal medicine in the cross-border collaborations and in
the optimized usage of research results, the accumulative public domain knowledge and
intellectual properties, clinical trial data and other contributory factors. Due to the
limitation of the length of this thesis, however, such a system description and comparison
is necessarily on a brief or conceptual level.
2.1 Regulatory Systems - US FDA and Chinese SFDA
2.1.1 Overview
Compared to the Chinese SFDA, the US Food and Drug Administration has a much
longer history and originated from very different constitutional assumptions and
congressional mandates. It is one of the United States oldest and most respected consumer
protection agencies. According to the official FDA website, FDA ensures that the food we
eat is safe and wholesome, that the cosmetics we use will not harm us, and that medicine,
medical devices, and radiation-emitting consumer products such as microwave ovens are
safe and effective. FDA also oversees feed and drugs for pets and farm animals. Authorized
by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public
health laws, the agency monitors the manufacture, import, transport, storage, and sale of $1
trillion worth of goods annually, at a cost to taxpayers of about $3.00 a person. In short,
FDA's work can be categorized into five types of jobs or activities: new products review,
monitoring, standards and regulations, research and enforcement.
While in China, the earliest drug management agency was established as an office under
the Ministry of Public Health after the founding of communist China in 1949. In 1982, a
national drug administration was established under the national economic commission.
Not until 1998, an official national drug administration was restructured under the direct
supervision of the State Council. In 2003, according to the restructuring plan of the State
Council approved by the First Plenary Session of the 10th National People's Congress and
"the State Council Notice on Government Structuring" (No.8.2003.), the current State
Food and Drug Administration (SFDA) was founded on the basis of the previously known
State Drug Administration. The State Food and Drug Administration is under the direct
supervision of the State Council, which is in charge of comprehensive supervision on the
safety management of food, health food, cosmetics, medical devices and drugs.
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From SFDA's official statements, its main responsibilities are:2 5
1. To organize relevant authorities to draft laws and regulations on safety management of
food, health food and cosmetics; organize relevant authorities to formulate comprehensive
supervision policy, work plan and supervise its implementation.
2. To exercise comprehensive supervision on the safety management of food, health food
and cosmetics in accordance with laws; organize and coordinate supervision work on the
safety of food, health food and cosmetics carried out by relevant authorities.
3. To organize and carry out investigation and impose punishment on serious safety
accidents of food, health food and cosmetics; delegated by the State Council, organize,
coordinate and conduct specific law-enforcement campaigns over safety of food, health
food and cosmetics nationwide; organize, coordinate and collaborate with relevant
authorities in carrying out emergency rescue work on serious safety accidents of food,
health food and cosmetics.
4. To comprehensively coordinate the testing and evaluation for the safety of food, health
food and cosmetics; formulate provisions on releasing of supervision information for
safety of food, health food and cosmetics in conjunction with relevant authorities and
monitor their implementation; sum up safety information of food, health food and
cosmetics from relevant authorities and release it to the public regularly.
5. To draft law and administrative regulations on drug administration and supervise their
enforcement; carry out protection system for certain traditional Chinese medicinal
preparations and administrative protection system for pharmaceuticals in accordance with
law or regulations.
6. To draft law and regulations on administration of medical devices and supervise their
enforcement; take charge of registration and regulation of medical devices; draft relevant
national standards, draw up and revise professional standards of medical devices,
manufacturing practice and supervise their implementation.
7. To be in charge of drug registration, draw up, revise and promulgate national standard of
drugs; draw up criteria for marketing authorization of health food; review and approve
health food; set up classification system for prescription drugs and OTC drugs; establish
and improve ADR monitoring system; be responsible for drug reevaluation, review drugs
to be withdrawn and formulate national essential medicines list.
8. To draft and revise good practices for drug research, manufacturing, distribution and use,
and supervise their implementation.
9. To control the quality of drugs and medical devices in manufacturers, distributors and
medical institutions; release national quality bulletin on drugs and medical devices on a
regular basis; investigate and punish illegal activities of producing and selling counterfeit
and inferior drugs and medical devices in accordance with the law.
10. To regulate radioactive pharmaceuticals, narcotics, toxics, psycho -tropics, and other
25 http://www.sfda.gov.cn/eng/
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controlled drugs and devices in accordance with law.
11. To draw up and improve qualification system for licensed pharmacists, supervise and
direct the registration of licensed pharmacists.
12. To direct national drug regulation and comprehensive supervision on the safety
management of food, health food and cosmetics.
13. To carry out exchanges and cooperation in drug regulation, relevant safety management
of food, health food and cosmetics with foreign governments and international
organizations.
14. To undertake other work assigned by the State Council.
As the above outline indicates, the Chinese SFDA is a new, independent, powerful,
fast-changing and also turbid administrative department of the PRC state government.
Comparing to US FDA, the scope of the power of SFDA is very similar.
2.1.2 Comparison of organization structures of FDA and SFDA
FDA
FDA is an administrative agency within the Department of Health and Human Services
and consists of eight centers/offices, which are listed below.
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Center for Drug Evaluation and Research (CDER)
Center for Food Safety and Applied Nutrition (CFSAN)
Center for Veterinary Medicine (CVM)
National Center for Toxicological Research (NCTR)
Office of the Commissioner (OC)
Office of Regulatory Affairs (ORA)
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According to FDA's official website, the Center for Drug Evaluation and Research (CDER)
is responsible for the evaluation of new drugs before they can be sold. The Center's
review of new drug applications not only prevents quackery, but it provides doctors and
patients with the information they need to use medicines wisely. From aspirin to cancer
treatments, CDER ensures that the benefits of drug products outweigh any known risks.
The Center has oversight responsibilities for prescription, over-the-counter and generic
drugs. This responsibility includes products that many consumers usually do not associate
as drugs, such as fluoride toothpaste, dandruff shampoos and sunscreens. CDER carefully
evaluates the benefits and risks of drugs and ensures that consumers have access, as
quickly as possible, to promising new treatments. The Center oversees the research,
development, manufacture and marketing of drugs. CDER ensures truth in advertising for
prescription drugs and monitors the use of marketed drugs for unexpected health risks. If
unexpected risks are detected after approval, CDER takes action to inform the public,
change a drug's label, or--if necessary--remove a product from the market.
SFDA
The organization structure of Chinese SFDA is as follows 27:
27 http://www.sfda.gov.cn/eng/
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Department of International Cooperation (Office for
Administrative Protection of Pharmaceutical)(Office
of Taiwan Hong Kong and Macao Affairs)
According to the official website of the SFDA 28, the responsibility of Department of
Policy & Regulations is to draft and revise drug administration law, regulations and
policies; organize relevant authorities to draft law and regulations for the safety
management of food, health food and cosmetics, and draw up comprehensive supervision
policies; make proposals for legislation plans; organize and carry out reviewing,
coordinating and issuing of administrative provisions; supervise administrative
law-enforcement and take charge of the work of hearing, undertake administrative
reconsideration, responding to prosecution, and compensation; give guidance on the
development of legal system in the food and drug administration system; organize and take
on news briefing, publicity and publishing of newspapers and periodicals.
The responsibility of Department of Food Safety Coordination is to organize relevant
authorities for drawing up work plans for the safety management of food, health food and
cosmetics and supervise their enforcement; carry out comprehensive supervision over the
safety management of food, health food and cosmetics in accordance with laws; organize
28 http://www.sfda.gov.cn/eng/
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and coordinate safety supervision carried out by relevant authorities on food, health food
and cosmetics; delegated by the State Council, organize, coordinate and unfold specific
law-enforcement inspection activities over safety of food, health food and cosmetics;
organize and coordinate with relevant authorities to improve reporting system of safety
accidents of food, health food and cosmetics; investigate and draw up emergency rescue
plans for the safety of food, health food and cosmetics; organize, coordinate and cooperate
with relevant authorities to carry out emergency rescue work; generally coordinate testing
and evaluation work for safety of food, health food and cosmetics, and give guidance to the
construction of food safety monitoring and evaluation system; carry out relevant work of
research and coordination in unified standard of food safety; organize drawing up research
plan for the methods and means of national key technical supervision on food safety and
supervise its implementation; collect information on safety of food, health food and
cosmetics, analyze and forecast safety situation, evaluate and prevent potential risks for
food safety; in conjunction with relevant authorities to formulate provisions on releasing of
safety information for food, health food and cosmetics and supervise their implementation;
sum up safety information for food, health food and cosmetics from relevant authorities
and release to the public on a regular basis; undertake other work assigned.
The responsibility of Department of Food Safety Supervision is to conduct investigation
and prosecution on extraordinarily serious accidents in accordance with laws; be
responsible for routine work of the Supervisor-General for National Food Safety and other
assigned work.
The responsibility of Department of Drug Registration is to draft and revise national drug
standards; formulate and update product lists of immediate packaging materials and
containers to drugs, and the requirements and standards for their medical use; take charge
of registering new drugs, drugs with national standards, import drugs, immediate
packaging materials and containers to drugs; implement protection system for traditional
Chinese medicinal preparations; give guidance to work of drug testing institutions
nationwide; draft criteria of marketing authorization for health food, and take charge of
approval of health food.
The responsibility of the Department of Drug Safety & Inspection is to organize the
implementation of drug classification system, review and promulgate OTC drug list,
formulate national essential medicines list; be in charge of drug reevaluation and review of
drugs to be withdrawn; set up and improve adverse drug reaction monitoring system; draw
up and revise Good Agriculture Practice (GAP), Good Manufacturing Practice (GMP), and
practice for preparations produced by medical institutions, and supervise their
implementation; formulate Good Laboratory Practice (GLP), Good Clinical Practice (GCP)
in consultation with relevant authorities and supervise their implementation; review drug
clinical study institutions; take charge of organizing and supervision on certification of
GMP in accordance with laws; regulate narcotics, toxics, psycho tropics and other
controlled drugs and devices; supervise the licensing of drug manufacturing, and
pharmaceutical preparations in medical institutions; draft criteria for licensing health food
manufacturers.
The responsibility of the Department of Drug Market Compliance is to draft and revise
Good Supply Distribution (GSP) and supervise its implementation; supervise quality of
drugs and medical devices of manufacturers, distributors and users, organize and
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implement national sampling and testing of drugs and medical devices, release national
quality bulletin for drugs and medical devices on a regular basis; investigate and prosecute
illegal activities of manufacturing and selling counterfeit and inferior drugs and medical
devices; supervise the licensing of distributors for drugs and medical devices, regulate
specialized market of Chinese crude drugs; be in charge of supervision on drug
advertisements, on-line drug information service and transactions, give guidance to the
reviewing of advertisement of health food.
2.1.3 Comparing important statistical data between SFDA and
FDA - new drug applications and approval rate
As briefly outlined above, although the administrative power, the organizational
structures between the Chinese SFDA and the US FDA are very similar, the statistical
data provides completely different stories.
The FDA has a continuous and scientific statistics for the new drug applications and
approvals. Exact numbers can be obtained from the FDA Website conveniently. While
the new drug application and approval data of SFDA is much more opaque, it is not
published or displayed in any statistics database. I collected the data from some scattered
news or research articles, in other word, the number of SFDA is not from the same source,
it's mixed. But I believe the following data is credible.
From January to June, 2006, the SFDA approved 4,635 applications in all. Among them,
imported drug 172, with 120 kinds; new drug approvals of 1,363, with 939 chemical
medicines, 356 traditional Chinese medicines, 67 biochemical medicines; 3,099 drugs
compliant with existing state standards, with 2,557 chemical medicines, 494 traditional
Chinese medicines. 29
In 2005, the SFDA approved 1,113 new drugs, in the same time; the FDA approved 81
new drugs. In 2004, the SFDA received 10,009 new drug applications and the FDA
received 148 applications.30
In 2003, the SFDA received drug registration applications of more than 17,000, and
approved 6,806 new drug applications, an increase of 128.5% over the previous year.
Approved 4,222 clinical trials of new drugs, an increase of 346.3% over the previous year;
Approved 1,351 manufacture applications, in increased 66.4% over the previous year.
Most of these approvals were granted after June of 2003, the time the new SFDA was
established.31
In the year 2005, the new drug approval ratio of SFDA/FDA=1,113/81. The multiple is
more than 13. And in the year 2004, the new drug application ratio of
29 From: http://www.sfda.net.cn/topic.php?filename=16016&extra= pae%3D2
30 From:
http://www.baidu.com/s?lm=0&si=&rnm= 10&tn=myie2dg&ie=gb2312&ct=O&wd=%B9%FA%BC%D2%CA%B3%C6
%B7%D2%A9%C6%B7%BC%EO%B6%BD%B9%DC%CO%ED%BE%D6+%C5%FA%D7%BC+%DO%C2%D2%
A9+%C9%EA%C.7%EB+%B8%F6&pn=40&cl=3
31 From: http://blog.sina.com.cn/u/47132c32010002kO
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SFDA/FDA=10,009/148. The multiple is more than 67.
During the last decade, particularly after the official establishment of the new SFDA,
with a much smaller budget the staff, the number of new drug applications and approvals
of SFDA far exceeds that of the US FDA. This fact has two immediate implications, one,
the Chinese pharmaceutical companies were highly productive in producing new drugs,
including generic drugs and foreign drugs as well as traditional Chinese medicinal
formulations, and two, a far more significant implication, the processes and quality
standards of approval must be very different.
2.1.4 Comparing approval processes between SFDA and FDA
FDA's application process is direct application and one level review. The CDER has a
60-day primary review (including formal review). These applications which do not meet
the standard or the technologic specifications should be rejected and disapproved.
The following charts highlight the NDA approval processes used by FDA:
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Figure 2.1.1 NDA review and approval processes used by FDA32
32 The CDER handbook of FDA, http://www.fda.gov/cder/handbook/
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Figure 2.1.2 Generic Drug (ANDA) Review Process used by FDA33
Consistent to the Chinese hierarchical administrative system, the SFDA's NDA
application process is in multiple levels and has at least two levels of reviews. The
applicant should submit the application to the regional (food) drug administrations for the
formal examination and an original review. Then the regional (food) drug administrations
should submit the application to the SFDA. After receiving the application materials, the
SFDA shall make an overall review of the application file. If it considers that the
33 The CDER handbook of FDA, http://www.fda.gov/cder/handbook/
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Consistent to the Chinese hierarchical administrative system, the SFDA's NDA
application process is in multiple levels and has at least two levels of reviews. The
applicant should submit the application to the regional (food) drug administrations for the
formal examination and an original review. Then the regional (food) drug administrations
should submit the application to the SFDA. After receiving the application materials, the
SFDA shall make an overall review of the application file. If it considers that the
application materials meet the relevant requirements, it would issue the applicant an
Approval Document on Drug Registration and a New Drug Certificate.
The reviewer of formal examination and an original review in regional (food) drug
administration is not the reviewer of the overall review in SFDA. So it means the process of
new drug application in China will have two independent reviews. The new drug applicant
must submit protocols and results of clinical trials. The processes for clinical trials and
new drug application (including imported drugs) reviews are illustrated as follows.
R&D situation and condition review
Application submissionw. Dossier content and format checking Inform applicant
Organize(5 days) and complete (30 days) site inspection and sampling, by drug administration at provincial level
Acceptance by SFDA (5days) Samples testing and standards verification
by drug testing institute (60 days)
Complementary data from applicant within
echnical evaluation by CDE (120/100 days*)I L 4 months by a whole
Supplementary data evaluation by CDE (40125 days*)
Rejection or return+ Final approval by SFDA (40/20 days*)
195/155 days *
Approval for clinical trialsi
.
-
Notification of clinical trial protocol and I Commencement of the clinical
the list of investigators to SFDA I trial.
Figure 2.1.3 SFDA- Application and approval procedure for clinical trials34
34 http://www.sfda.gov.cn/eng/
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* Notes: Days before slantly line
refer to timeline for ordinary
approval and that after slantly line
are the timeline for fast track
approval. All in working days.
Applicant
Send the raw materials of the standard products
to the National Institute for the Control of
Pharmaceutical and Biological Products
Submit the clinical trial materials and other modified and supplemented
materials to the (food) drug administration of the province, autonomous region
or municipality directly under the Central Government where it is located
The (food) drug administration of the province, autonomous region or
municipality directly under the Central Government conducts a formal
examination over the application materials (30 days)
I.
I
SFDA acceptance (5
days)
IThe institute for drug control makes an
inspection over the selected samples (30 days)
CDE review (120/100 days) Supplement materials in four months for once
CDE review the supplemental materials (40/25 days)
Approve to manufacture (195/155 days)
Figure 2.1.4 SFDA - New drug examination and approval process 35
35 http://www.sfda.gov.cn/eng/
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Notes : Days before slanted lines
refers to the timeline for ordinary
approval and that after slanted
lines are the timelines for fast
track approval (All in working
days).
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If necessary, a site inspection for the R&D and
production conditions should be fulfilled
Dossier content and format checking; notification of quality test and specifications verification, by SDA(30 days)
Technical evaluation by CDE (120/100 days*)
.Rejection 1
T
Samples testing and standards verification
by NICPBP (85 days)
Complementary data from applicant within 4 months I
Supplementary data evaluation by CDE (40125 days*)
or return Final approval by SFDA (40120 days*)
Approval for clinical trials
Notification of clinical trial protocol and [ Commencement of the clinical
the list of investigators to SFDA trial
Figure 2.1.5 SFDA - Application and approval procedure for imported drugs (1)36
36 http://www.sfda.gov.cn/eng/
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*Notes. Days before slantly line
refer to timeline for ordinary
approval and that after slantly line
are the timeline for fast track
approval. All in working days.
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Figure 2.1.6 SFDA - Application and approval procedure for imported drugs (2) 37
37 http://www.sfda.gov.cn/eng/
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Figure 2.1.7 SFDA - Supplementary
drugs (1)38
application and approval procedure for imported
38 http://www.sfda.gov.cn/eng/
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Figure 2.1.8 SFDA - Supplementary
drugs (2) 39
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The (food) drug administration of the province, autonomous region or municipality
directly under the Central Government organizes an on-spot inspection over the
manufacturing process and conditions, selects samples and gives the designated
institute for drug control a sample inspection notice. ( 30 days )
SFDA acceptance
(5 days)
CDE review (80 days)
SFDA review (40 days)
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Figure 2.1.9 SFDA - Drug Supplementary Application and Examination & Approval
process (1) 40
40 http://www.sfda.gov.cn/eng/
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Figure 2.1.10 SFDA -
procedure (2)41
Drug Supplementary Application, Examination & Approval
2.1.5 Comparing NDA review standards between SFDA and
FDA
Before making direct comparison, we need to make sure that we are comparing apples
and oranges. First of all, the term "new drug" is different between China SFDA and the
US FDA. Most of the new drugs in the United States refer to the true newly created
entities. But many "new drugs" in the statistics are not actually new drugs, but drugs that
have already been on the market for some time, but are not registered yet as a new drug.
41 http://www.sfda.gov.cn/eng/
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This partially explains why the number of new drug application is so large in China in
recent years; the SFDA was playing a catch-up game.
Second, in case of US FDA, the standards of new drug approval are universally and
equally applied and extremely stringent. The processes and requirements of new drug
approval must accord with a series of well established requirements or standards, which
are usually well understood by pharmaceutical companies and have been in use or in
practice for a long time. The approval/application ratio of SFDA is far higher than that of
the FDA and the standards of approval in SFDA are often arbitrary and subject to
reviewers' personal discretion or administrative corruptions. Of particular note, the power
in the Chinese SFDA system are hierarchically distributed among the regional (provincial)
and central administrations, which creates a structure-induced divergence of standards:
each province has an incentive to obtain more drug approvals for pharmaceutical
companies in its own geographical region for economic development and tax revenue
purposes, and as a consequence, there has been a tendency to relax the review standards.
For the central SFDA office, the reviewers must somehow balance the number of new
drug approvals among various provinces, and as a result, the de-facto standards are not
that consistent across different provinces.
The following paragraphs further compare the specific aspects of the new drug
application, examination/review and approval requirements or standards. Due to the
limitation of the length of this thesis, I would focus on areas relevant to the thesis and
also at a much outlined level. The description is mostly a summary of information from
the official government websites (FDA and SFDA).
2.1.5.1 New drug application requirements
In SFDA, Application to Market a New Drug for Human Use or as an Antibiotic Drug for
Human Use, for example, NDAs may consist of as many as 15 different sections: Index;
Summary; Chemistry, Manufacturing, and Control; Samples; Methods Validation;
Package and Labeling; Non-clinical Pharmacology and Toxicology; Human
Pharmacokinetics and Bioavailability; Microbiology (for anti-microbial drugs only);
Clinical Data; Safety Update Report (typically submitted 120 days after the NDA's
submission); Statistical; Case Report Tabulations; Case Report Forms; Patent Information;
Patent Certification; and Other Information. In the SFDA, the Measures for the
Administration of Drug Registration have 5 annex to regulate the registration classification
and the requirements for application materials: Traditional Chinese Medicines, Chemical
Drugs, Biological Products, Drug Supplementary, and Drug Re-registration. In each
document there are specific requirements for the drug registration.
Most of the SFDA requirements, from the perspective of content and formalities, are very
similar to US FDA requirements. It is widely believed that the SFDA was established
largely following the FDA's model. But these requirements do have differences.
The registration classification for Traditional Chinese Medicine (TCM) is a special type of
SFDA drug registration system. The requirements of TCM have some common
requirements such as summation of materials, pharmaceutical materials, materials of
pharmacology and toxicology, clinical materials, etc. But there are some extraordinary
requirements, such as the source of medicine and the identify data; the environment of
material production, botanical growth characteristics, formulation description, plant or
-43 -
transplant techniques; as well as provision of the samples of plant and minerals. In case of
a plant sample, it should include flower, fruit, and seed, etc. As specified by the Drug
Administration Law of the People's Republic of China, the required application materials
of Traditional Chinese Medicines, Chemical Drugs, and Biological Products are
summarized into the tables in the following pages.
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Requirements for Application Materials of New Drug Application (Chinese SFDA)
Traditional Chinese Medicines and Chemical Drugs Biological Products
Natural Medicines
1.Name of the drug 1.Name of the drug 1.Name of the drug
. 2.Certificate documents 2.Certificate documents 2.Certificate documents
3.Goal and the reason of project 3.Goal and the reason of project 3.Goal and the reason of project
4.Research result summary and 4. Research result summary and 4. Research result summary and
• evaluation evaluation evaluation
5.Draft of drug specifications and 5. Draft of drug specifications and 5. Draft of drug specifications and
explanation of draft and reference r explanation of draft and reference • explanation of draft and reference
6.Packing, tag design draft 6.Packing, tag design draft 6.Packing, tag design draft
7.Summary of pharmaceutical 7. Summary of pharmaceutical 7. Summary of pharmaceutical research
research materials research materials materials
8.Source of medicine and the identify 8.Research materials and 8.Research materials of manufactured
"i data • literature materials of " raw and processed materials
0 manufacture raw, processed
E materials, preparation
CO prescription and technique
9.Environment of drug, growth 5 9.Trial materials and literature 9.Research materials of original fluid or
character, configuration description, 8 materials of the corroborant 8 raw material manufacture technique,
plant or implantation technique, chemistry structure or assured theory, experimental data, and
machining and facture, etc. configuration validate data
10.Draft of medicine standard and the 10O.Trial materials and literature 10.Research material of preparation
explanation draft, providing medicine materials of quality research prescription and technique, source,
standard matters and materials quality standard and relevant literature
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thereof.
11 .Provide samples of plant and
mineral, the plant sample should
include flower, fruit, and seed, etc.
12.Research and literature material of
manufacture techniques, source of
supplementary materials and quality
standards
13.Trial materials and literature
materials of the corroborant
chemistry structure or configuration
14.Trial materials and literature
materials of quality research
15.Draft of medicine standards and
the explanation for the draft, provide
the medicine standard matters and
materials thereof
11 .Draft of medicine standards
and the explanation for the draft,
provide the medicine standard
matters or comparison matters
12.Report of sample inspection
13. Source, quality standard and
inspection report of raw material
medicines and supplementary
materials.
14.Trial materials and literature
materials of the drug stability
research
15.Reason and quality standard to
the wrapper and container of
direct contact product
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14.Primary stability research materials
15.Reason and quality standard to the
wrapper and container of direct contact
product
of supplementary materials
11.Quality research materials and
relevant literature, including the
preparation and demarcate of reference
sample or comparison sample, and the
comparison to the alike product
marketed at home and overseas
12.Manufacture and examination record
of clinic trial samples
13.Draft of manufacture and examine
regulations, the explanation draft and
examine method, validate materials plus
---
S16.Report of sample inspection
17.Trial materials and literature
materials of the drug stability
research
18.Reason and quality standard to the
wrapper and container of direct
contact product
19.Summary of pharmacology and
toxicology
20.Main pharmacodynamics trial
materials and literature materials
21.General pharmacological research
trial materials and literature materials
and
16.Summary of
and toxicology
pharmacology
17.Main pharmacodynamics trial
materials and literature materials
18.General pharmacological
research trial materials and
literature materials
19.Acute toxic trial materials and
literature materials
20.Long-term toxic trial materials
and literature materials
21.Research materials and
literature materials of imitability
(local, body, photosensitive
toxicity ), hemolytic and local
stimulus ( blood vessel, skin,
mucosa, muscle, etc ) , such a
special safety trial relates to local
or systemic administration
22.Trial materials and literature
materials of interaction effect of
multi-component in
16.Summary of
toxicology
pharmacology and
17.Main pharmacodynamics trial
materials and literature materials
18.General Pharmacological research
trial materials and literature materials
19.Acute toxic trial materials and
literature materials
20.Long-term toxic trial materials and
literature materials
21.Animal pharmacokinetics trial
materials and literature materials
22.Mutation test materials and literature
materials
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22.Acute toxic
literature materia.
trial materials
---
pharmacodynamics,
pharmacokinetics
toxicity,
23.Mutation test materials and
literature materials
24.Reproductive toxicity trial
materials and literature materials
23 .Long-term toxic trial materials and
literature materials
24.Research materials and literature
materials of imitability (local, body,
photosensitive toxicity ), hemolytic
and local stimulus ( blood vessel,
skin, mucosa, muscle, etc ) ,
dependent trial, special safety trial
related to local or systemic
administration
25.Mutation test materials and
literature materials
26.Reproductive toxicity trial
materials and literature materials
27.Carcinogenicity test materials and
literature materials
27.Trial materials and literature
materials of non-clinic
pharmacokinetics
23.Reproductive toxicity trial materials
and literature materials
24.Carcinogenicity test materials and
literature materials
25.Immune toxicity and/or
immunogenicity research materials and
literature materials
26.Research materials and literature
materials of hemolytic and local
stimulus ( blood vessel, skin, mucosa,
muscle, etc ) such a special safety trial
related to
administration
local or systemic
27.Drug efficiency, toxicity,
pharmacokinetics interactive trial
materials and literature materials of
multi component of compound
preparation
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25.Carcinogenicity test materials
and literature materials
26.Dependent trial materials and
literature materials
____j
28.Animal pharmacokinetics
materials and literature materials
trial
29.SuI1mmr rxy of clinic trial
30.Plan of clinic trial and draft
research project
31.Handbook of clinic researcher
32.Draft of letter of consent and
knowledge, letter of approval from
ethics committee
33.Clinic trial report
28.Dependent trial materials and
literature materials
1129.S ,m y of -clinic
home and overseas
trial materials4 ItL% L
34.Brief research summary
pre-clinical trial
of the
35.Summary and trial data which
relates to improving the technique,
perfecting the quality standard and
pharmacology and toxicology, during
the clinic trial
36.Amended content and amended
reason to the authorized regulation
37.Stability trial research materials
38.Manufacture and examination record
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28.Summarize of the clinic trial
materials home and overseas
29.P!an -of clinic tria;l and drAaft of
research project
30.Handbook of clinical
researcher
31.Draft of letter of consent and
knowledge, letter of approval
from ethics committee
32.Clinic trial report
30.Plan of clinic trial and draft of
research project
31.Draft of letter of consent and
knowledge
32.Handbook of clinical researcher and
letter of approval from ethics committee
33.Clinic trial report
----
of three continual samples
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2.1.5.2 Pre-clinical research
As part of FDA requirements, a sponsor must first submit data showing that the drug is
reasonably safe for use in initial, small-scale clinical studies. Depending on whether the
compound has been studied or marketed previously, the sponsor may have several options
for fulfilling this requirement: (1) compiling existing non-clinical data from past in vitro
laboratory or animal studies on the compound; (2) compiling data from previous clinical
testing or marketing of the drug in the United States or another country whose population
is relevant to the US population; or (3) undertaking new preclinical studies designed to
provide the evidence necessary to support the safety of administering the compound to
humans. During preclinical drug development, a sponsor evaluates the drug's toxic and
pharmacologic effects through in vitro and in vivo laboratory animal testing. Genetic
toxicity screening is performed, as well as investigations on drug absorption and
metabolism, the toxicity of the drug's metabolites, and the speed with which the drug and
its metabolites are excreted from the body. At the preclinical stage, the FDA will
generally ask, at a minimum, that sponsors: (1) develop a pharmacological profile of the
drug; (2) determine the acute toxicity of the drug in at least two species of animals, and (3)
conduct short-term toxicity studies ranging from 2 weeks to 3 months, depending on the
proposed duration of use of the substance in the proposed clinical studies.
In the SFDA, "The pre-clinical trial of new drugs for applying for drug registration" must
include: synthetic techniques, extraction methods, physical and chemical properties,
purity, choice of form of this drug, selection of prescriptions, preparation techniques,
inspection methods, quality indicators, stability, pharmacology, toxicology, nucleic
animal dynamics, etc. As for traditional Chinese medicine preparations, the sources and
processing of the original medicine materials, etc. shall also be included. As for biologic
products, the: sources, quality standards, preservation conditions, biological features,
inheritance stability and immunological study of the primary raw materials such as
microbial and toxic species, cell line or organism, etc. shall also be included. The agency
for pre-clinical trial of new drugs for applying for drug registration in China is Regional
Drug Administration and Central SFDA. After the preclinical trials, the applicant must
perform clinical trials.
The emphasis on the part of SFDA in evaluating preclinical trials, as the above two
paragraphs show, appears to be partially on the chemical and physical characteristics of
the proposed new drugs, to make sure its quality/quantity consistency.
2.1.5.3 Clinical trial of drugs
In the United State NDA application process, the applicant must provide sufficient
information, data, and analyses to permit FDA reviewers to reach several key decisions,
including: whether the drug is safe and effective for its proposed use(s), and whether the
benefits of the drug outweigh its risks; whether the drug's proposed labeling is
appropriate, and, if not, what the drug's labeling should contain; whether the methods
used in manufacturing the drug and the controls used to maintain the drug's quality are
adequate to preserve the drug's identity, strength, quality, and purity. The purpose of
preclinical work, such as animal pharmacology/toxicology testing, is to develop adequate
data to warrant a decision that it is reasonably safe to proceed with human trials of the
drug. Clinical trials represent the ultimate pre-market testing ground for approvable drugs.
During these trials, an investigational compound is administered to humans and is
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evaluated for its safety and effectiveness in treating, preventing, or diagnosing a specific
disease or condition. The results of this testing will comprise the single most important
factor in the ;approval or disapproval of a new drug.
In SFDA, an applicant shall conduct clinical trials when applying for the registration of a
new drug. Such clinical trials are divided into four phases: I, II, III and IV. Before a new
drug is approved for marketing, phases I, II, and III clinical trials shall be conducted. Under
certain circumstances, the applicant may, upon approval, only conduct phases II and III
clinical trials or only phase III clinical trials. Phase I clinical trials are the preliminary trials
on clinical pharmacology and human body safety evaluation, which aim to observe the
degree of tolerance of the human body against the new drug and the drug dynamics, and
provide the basis for working out the dosage administration scheme. Phase II clinical trials
are the preliminary evaluation of the treating effects, which aim to preliminarily evaluate
the treating effect and safety of the drug on the target patients with the applicable disease,
and also to provide the basis for the determination of study design and dosage
administration scheme for the clinical trial in phase III. Various methods may be employed
for the study design of this phase in light of the specific study purpose, including the
randomized controlled trial. Phase II clinical trials represent the confirmation phase of the
treating effect, which aim to further verify the treating effect and safety of the drug on the
target patient with the applicable disease, to evaluate the relationship between interest and
risk, and to eventually provide adequate basis for the examination of the drug registration
application. Generally, the trials shall be randomly controlled with sufficient samples.
Phase IV clinical trials: the phase of application study conducted by the applicant
independently after the new drug comes onto the market, which aims to examine the
curative effect of the drug and the adverse reactions when it is widely used, to evaluate the
relationship between interest and risk when the drug is used in ordinary or special groups
and to improve the dosage administration.
From a comparative note, the four phases of clinical trials are defined very similarly
between the two regulatory systems. Of note, in response to growing reports of adverse
side-effects related to the drugs on the market, the Chinese SFDA has also established
and funded a special agency by the name of Drug Post-Market Side-Effect Surveillance
Center in an effort to timely discover and act on the effects produced by the existing
approved drugs. This thesis author, by and through his Chinese company, was engaged to
provide a consulting report on the history, structure, process and evolution of the US
FDA's post-market drug monitoring system. Many of the recommendations in this
consulting report were eventually adopted.
2.1.5.4 Investigational new drug (IND) applications
Investigational New Drug application process (IND) of the FDA is the result of a
successful preclinical development program. The IND is also the vehicle through which a
sponsor advances to the next stage of drug development known as clinical trials (human
trials). Generally, this includes processes which generate data and information in the
following three broad areas: animal pharmacology and toxicology studies; preclinical
data to permit an assessment as to whether the product is reasonably safe for initial
testing in humans; manufacturing information, including information pertaining to the
composition, manufacture, stability, and controls used for manufacturing the drug
substance and the drug product. This information is assessed as to ensure the company
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can adequately produce and supply consistent batches of the drug; and proposed Clinical
Protocols and Investigator Information, which include detailed protocols for proposed
clinical studies to assess whether the initial-phase trials will expose subjects to
unnecessary risks. Besides that, information on the qualifications of clinical
investigators-professionals (generally physicians) who oversee the administration of the
experimental compound--should be provided to assess whether they are qualified to
fulfill their clinical trial duties.
In SFDA, there is not such a distinct process similar with IND. The function is performed
by the combined processes of Pre-Clinical Trial of New Drugs, the Clinical Trial of
Drugs, and the Administration of Clinical Trials. These requirements, in essence, would
match the requirements of Pre-Clinical Research and IND in the SFDA.
2.1.5.5 Time limit of new drug review
Every year in the FDA, there is different submission cohorts (e.g., NMEs, priority NMEs,
NDAs, etc). Many submitted are approved within a year of submission, but some are not
if the FDA has additional questions or because FDA standards have not been met. An
effect of submission trends on statistics shows that, in times where the number of
submissions is increasing, the older applications have less impact on the median approval
time; in times where the number of submissions is decreasing, older applications may
dominate the median approval times. The total approval time is the time from first
submission to approval. It includes all FDA review time as well as the time spent by the
sponsor in responding to FDA questions. There is also a priority NDA application
category in the FDA process for policy reasons such as for urgently needed drugs. In
1998, there were 25 priority DNAs approved with a median time of 6.4 months. In 2002,
there were 11 priority DNAs approved with a median time of 16.3 months. We could
perceive two trends: (1) the priority NDAs approval number is decreasing from 1998 to
2002; (2) the Median Approval Time is increasing. The following charts show the
situation of Priority NDAs Approved in the years 1998 and 2002:
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Figure 2.1.11 Priority NDAs Approved by FDA in the years 1998 and 2002 42
42 Median Approval Time Statistics, www.fda.gov
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The exact data of SFDA's total approvals is not published, but the relevant laws regulate
the time limit of drug review. The Measures for the Administration of Drug Registration
change the old regulation about the time limit of drug review. The time span of drug
review decreased in most of the steps. The content and time limit of SFDA drug review is
summarized in the table below:
Acceptance
Time limit
Items should finished Finish time limit
Provincial
registration
administrat
ion
5 days
The
provincial
institute
for drug
control
SFDA 5 days
Imported
drug 30
days
NICPBP
CDE
Acceptance; on-spot
inspection; sample; send a
notice to the designated
institute for drug control;
submit the examination
opinions; inspection
report and application
materials to the SFDA
and notify the applicant
Check and test the
samples, submit
inspection report and
verification opinions to
the SFDA
Check and test the
samples, verify the drug
standards
Accept the review
Accept the review, and
notify the NICPBP
Arrange the check and
test
Check and test the
samples, verify the drug
standards
Review the standard
Technology review
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Steps Agent
30 days
Generic drugs: 30
days; special drugs
and antibiotics: 60
days
Generic drugs: 60
days; special drugs
and antibiotics: 90
days
5 days
30 days
5 days
60 days
20 days
Clinical Trial and
Manufacturing of
New Drugs: 120 days
(expedite 100 days)
Drugs with Existing
0d
3-
SFDA examine and approve
2.1.5.6 Communication between reviewer and applicant
During the course of reviewing an application, the CDER of the US FDA usually
communicates with sponsors about scientific, medical, and procedural issues that arise
during the review process. Communications may take the form of telephone
conversations, letters, faxes or meetings. This system could avoid needless investment
and repeated research, and reduce the misplay and the cost.
The communication system between the reviewer and the applicant is not established in
the SFDA process. It lacks communication and is considered to be a source for
bureaucratic misunderstanding, arbitrary decisions and rent-seeking corruptive activities.
2.1.5.7 Modern (western type) and traditional medicines
In China, the SFDA classifies drugs into "Modem and traditional medicines." The
modem medicines usually refer to drugs developed by modem scientific technological
methods and the traditional medicines generally refer to the methods used for preventing
and treating disease according to the traditional medicinal theory. The main sources of
traditional medicines include herbal (plant) medicines, animal medicines, and mineral
medicines.
In a summary note, the explicit requirements of new drug applications are very similar
between the two systems, but the de-facto or execution standards and the outcomes are
very different. The FDA's requirements and standards are very transparent and well
published; while the SFDA's substantive standards are largely opaque and subject to
reviewer's arbitrary discretion. A significant difference is that there is no official means
of communication between the reviewers and the applicants in the SFDA's new drug
examination process.
2.1.6 Trend of SFDA under the context of globalization
Under the globalization context, particularly in the last decade, the Chinese drug
registration laws and regulations have been amended and redrafted several times, in an
effort to harmonize with international practices. SFDA's new regulations have followed
FDA's model and practices in many substantive aspects. In promoting availability of
commonly used OTC drugs, as part of medical insurance reform, SFDA released its first
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State Standards: 80
days
Supplementary
materials: 40 days
(expedite 30 days)
Supplementary
application: 60 days
40 days
list of over-the-counter (OTC) medications in June 1999, and in 2000, the state began to
regulate OTC and prescription drugs separately. SFDA did so to encourage patients to
purchase OTC medicines for less serious diseases, thereby reducing the country's overall
medication expenditures and hospital visits. As a systematic quality control measure, the
SFDA requires pharmaceutical companies to obtain GMP certificates to be licensed to
sell their pharmaceutical products in China. In 2005, SFDA launched a regulation on drug
research and supervision management aimed at enforcing the GLP to investigative drugs,
traditional Chinese medicine injections and biotechnology products. The regulation aims
to help China's drug research and development gain international recognition.
The old regulations have no restriction to the applicant, so individuals could be a new drug
applicant. The amended regulations change the requirement, and at the same time the
regulations distinguish the domestic applicant and foreign applicant. Now, an applicant for
drug registration refers to an institution that files an application for drug registration, bears
the corresponding legal liabilities, and holds the drug approval certification documents
after the application is approved. A domestic applicant shall be an institution that is
lawfully registered within China who bears civil liabilities independently, while an
overseas (foreign) applicant is a lawful overseas drug manufacturer. When an overseas
applicant applies for the registration of drug import, its office based in China or an
entrusted agency within China shall go through the formalities for the registration of the
imported drug(s).
In terms of patents, the new regulations require that the applicant shall provide
explanations on its ownership and statement of no infringement upon the patents of others.
If any dispute arises after the application for drug registration is approved, the parties
concerned shall settle the dispute through negotiations by themselves, or through the
patent administrative department or the people's court pursuant to the relevant laws and
regulations. With regard to generic drugs, an applicant may file a registration application
within 2 years before the expiration of the patent of that drug. The SFDA could issue to it
the registered number of drug approval, an Imported Drug Registration Certificate or the
Pharmaceutical Product Registration Certificate after the patent expires.
The above are some highlights of the fast-tract convergence of laws and regulations of
the Chinese SFDA toward the international and US standards or customary practices,
which provide regulatory foundation for creating and capturing value in the cross-border
development and marketing of pharmaceutical products, this is also true to herb-derived
pharmaceutical products. The execution and enforcement of Chinese SFDA laws and
regulations remain a major concern for the international players, however, despite the
plausible laws, processes and standards in the print forms.
2.2 Modernization of Chinese Herbal Medicine
The following pages address the central theme of this thesis, how to modernize Chinese
medicine so that such pharmaceutical products can become ethical drugs and enter the
mainstream international markets, particularly the US market which is the single largest
market in the world and will likely remain so for a long period of time. In this section of
the thesis, the author will not only write about the development of refined chemical
compounds from Chinese herbal medicine, a critical pathway I call "original pathway" or
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"singleton pathway," but also address the hypothesis of developing future ethical drugs
from Chinese mixed formulas, I term it the "mixed formula pathway" or "alternative
pathways." The former has many successful examples in the past, but the pathway is
becoming less productive and increasingly costly lately; the latter is built on a different
philosophy and perceivably much less expensive, may represent one of the "disruptive"
solutions to the healthcare crisis in the world. This thesis will take several pages to
describe the quality assurance measures Chinese companies are currently using and the
"fingerprint" technology that may hold promise to partially resolve the standardization
and quality consistency issues that are often associated with raw herbal products or mixed
herbal formulas.
2.2.1 Singleton drugs
One potential development of Chinese herbal medicine is to derive singleton (chemical)
drugs from therapeutically effective compound in herbal extracts. Artemisinin, derived
from Artemisia annua L (qinghao) is a good example of this kind of development.
Chinese herbal medicines have been used by Chinese people to resolve many health
problems that are not curable by western chemical drugs, so Chinese herbal medicines
may be viewed as valuable research indicator for new chemical drugs. The major
advantage of this method is that, once the effective therapeutic compound is identified,
the structure of it may be modified and effects optimized using the same chemical
screening technology and molecular signaling pathway validation technologies
conventionally used in the chemical drug development. Such new drug, once successful
developed, is a chemical drug in fact, rather than Chinese herbal medicine. The standard
drug development processes, such as pre-clinical research and clinical trials will be done
as if it were is a western chemical drug. The major disadvantage of this type of singleton
drug is the high level of purification and it often targets a singular mechanism or
molecular signaling pathway and produces a specific effect. Such effect may be very
efficacious in the short run once introduced into the human body, but its action is often
transient and sometimes with inevitable side-effects.
For many helpful Chinese herbal medicines, as discussed at length at the beginning
sections of this thesis, the therapeutic effects only display when the whole herb with
many chemical compounds or, more often, many herbal and other ingredients are used
together as a whole as mixed formula. When examined separately, each of the compounds
may not have evident therapeutic effect on targeted molecular pathways or clinical
diseases, and some of them may even show increased toxicity. For example, a drug
named Zemaphyte, compounded from 10 herbs used by traditional Chinese medical
practitioners, was once found to have therapeutic effect on eczema. As a whole, it is
effective in treating erythema (redness), surface damage to the skin, sleep disturbance and
itching, but no single herb was found to be singularly responsible for this efficacy. For
these mixed formula medicines, it would be hard to convert them into singleton (chemical)
drugs.
In short, the: chemical purification method may greatly leverage the technologies
currently used by western chemical drug development, and is easy to be understood by
scientists practicing in western pharmaceutical companies, but it can only realize partial
value in Chinese herbal medicine.
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2.2.2 Botanical drugs
The US FDA now recognizes botanical drugs as a special class; the following
summarizes the guidance from FDA websites for botanical drugs:
1. Botanical drugs are derived from vegetable matters and are usually prepared as
complex mixtures. Their chemical constituents are not always well defined. In many
cases, even the active constituent in a botanical drug is not identified, nor is its
biological activity well characterized. Therefore, the CMC documentation that should
be provided for botanical drugs may be different from that for synthetic or highly
purified drugs, whose active constituents can be more readily chemically identified
and quantified.
2. In such circumstances, FDA will rely instead on a combination of other tests (e.g.,
spectroscopic or chromatographic fingerprints, chemical assay of characteristic
markers, and biological assays), controls (strict quality controls of the botanical raw
materials and adequate in-process controls), and process validation (especially for the
drug substance) to ensure the identity, purity, quality, strength, potency, and
consistency of the botanical drug.
3. Botanical drug products that are derived from a single part of a plant (e.g., leaves,
stems, roots, seeds), or from an alga or macroscopic fungus (e.g., a mushroom), are
not considered to be fixed-combination drugs within the meaning of 21 CFR 300.50
and 330.10(a)(4)(iv). Consequently, they would not have to meet the requirements
for combination drugs, principally the need to demonstrate that each component or
active ingredient makes a contribution to claimed effects.
4. Botanical drugs composed of multiple parts of a single plant species, or of parts from
different plant species, currently are subject to the combination drug requirements.
However, FDA intends to propose revisions to its regulations to allow for the
exemption of such botanical drugs from application of the combination drug
requirements under certain circumstances.
This is a very significant change in the US FDA regulations and may represent a major
opportunity for creating and capturing value in Chinese herbal medicines as single herbs.
But under this guidance, only a relatively smaller number of Chinese herbal medicines
can be qualified as botanical drugs by FDA, because most Chinese herbal medicines use
multiple herbs.
2.2.3 Combination drugs
Most Chinese herbal medicines must meet the requirements of combination drugs before
they can be approved by FDA as new drugs. This means that the efficacy and safety of
each component or active ingredient must be individually demonstrated. This imposes the
greatest difficulty for Chinese herbal medicines to be approved by FDA as new drugs
because Chinese herbal medicines are based on a holistic theory. The ingredients are not
simply mixtures of its parts, but are meant to constitute a new therapeutic system, a
system in which 1+1 may be greater than 2.
Chinese herbal medicines prepared from smaller number of herbs may be more likely to
be verified. Fufang Danshen Diwan, a Chinese herbal medicine prepared from salvia
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miltiorrhiza (danshen), panax notoginseng (sanqi), and cinnamomum camphora
(bingpian) became the first Chinese herbal medicine gaining the FDA's IND approval to
enter clinical trial in the US in 1997, although little progress has been obtained due to the
inconsistent results on efficacy.
Some Chinese herbal medicines met the FDA's requirements for combination drugs, but
the FDA's evaluation criteria are not suitable to assess the holistic therapeutic effects of
most Chinese herbal formulas. Some Chinese pharmaceutical companies, such as the
famous traditional Chinese herbal medicine manufacturer Tong Ren Tang, are actively
exploring ways to bring Chinese herbal medicine to the world. One way is to spread the
theory and philosophy of Chinese medicine, and at the same time attempt to find a
suitable evaluation method to scientifically reflect the nature of Chinese herbal medicine.
2.2.4 Quality, standards and consistency - problems and
improvements in producing Chinese herbal medicine
Chinese herbal medicine has long been known to have great variation and inconsistency
from batch to batch and from producer to producer. To improve the standardization and
quality control of Chinese herbal medicine, China has introduced Good Agriculture
Practice (GAP), Good Laboratory Practice (GLP), Good clinical Practice (GCP), Good
Manufacturing Practice (GMP), and Good Supply Practice (GSP) to regulate herbal
medicine production.
Now, with the improved quality standards there are several Chinese herbal medicines that
have obtained FDA's IND approval and are stepping into clinical trials. For example,
Fuzheng Huayu Piece, manufactured by Shanghai Sundise Chinese Medicine Technology
Development Co., Ltd, has obtained FDA's IND clearance in January 2007 to start phase
II clinical trial in the US for the treatment of liver disease. The phase II clinical trial is
planned to be finished by 2009, involving 120 patients. The table on the following page
summarizes the progresses:
Drug Manufacturer Targeted Progress or status
disease
Fufang Tasly Group cardio-vas IND approval by FDA to enter
Danshen cular clinical trials in the US in 1997.
Diwan disease
Kanglaite Zhejiang cancer of Drug registration certificate issued
Injection Kanglaite the by the Health Ministry of Russia in
Pharmaceutical pancreas December 2003.
IND approval by FDA to enter
phase I clinical trials in the US in
2001. Enter phase II clinical trials in
2003.
SunRecome Shanghai Green cancer IND approval by FDA to enter
Valley phase I clinical trials in the US in
Pharmaceutical 2005.
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Xuezhikuang Beijing WBL cardio-vas IND approval by FDA to enter
Peking University cular phase II clinical trials in the US.
Biotech Co., Ltd. disease
Fuzheng Shanghai Sundise Liver IND approval by FDA to enter
Huayu Piece Chinese Medicine disease phase II clinical trials in the US in
Technology January 2007
Development Co.,
Ltd.
Guizhi Fuling Jiangsu Kanion Gyneco-pa IND approval by FDA to enter
Jiaonang Pharmaceutical thy phase II clinical trials in the US in
November 2006
Yinxing Xingling angina IND approval by FDA to enter
Tongzhi Pharmaceutical phase III clinical trials in the US.
Weimaining Huahe cancer IND approval by FDA to enter
Pharmaceutical phase II clinical trials in the US.
Despite the above very promising and significant inroad of Chinese herbal medicines
toward the western mainstream market, no Chinese herbal medicines have yet obtained
FDA's approval to be sold as new drugs in the US, because there are multiple problems
from material preparation to pre-clinical research, from clinical trials to manufacturing of
the herbal medicines. In short, there have been great improvements, but still a long way
to go. In the following paragraphs, we look at the special challenges and potential
solutions.
2.2.4.1 Fingerprinting technology and material quality control
This first basic issue is the quality of the herbal material. FDA requires that materials
used by a drug must be traceable, under good quality control and consistent.
Most Chinese medicinal herbs are complex compounds of many ingredients. Further,
herbs with the same name can display different level of therapeutic effects if they are
grown in different places, collected in different periods, or processed by different
procedures. Quality control and consistency maintenance of materials are more difficult
for Chinese herbal medicines than for western chemical drugs. Lack of suitable
measurement standards of medical herbs deteriorates the problem. Chinese
Pharmacopoeia is the national code used to govern the quality of drugs. Chinese medical
herbs and herbal pieces prepared for prepared Chinese medicine appeared in Chinese
Pharmacopoeia (Volume I) in 1963 for the first time. The standards in this book describe
the herbs and herbal medicines largely according to their appearances and other physical
characteristics, apparently lack scientific methods to delineate quality requirements and
ignored the issues of hazardous heavy metals and residual of pesticide, which have
recently raised concerns among consumers of Chinese herbal medicine. The lacking of
scientifically verifiable quality standards, for a long time, results in mixing of both high
quality herbal and low quality materials, great variances in the prepared herbal medicines
and inconsistent efficacy in the marketed herbal medicines. The current edition of
Chinese Pharmacopoeia was issued in 2005, in accordance with the principles decided by
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the 8th Chinese Pharmacopoeia Commission. The new Pharmacopoeia takes into
consideration of advanced technology and experimental methods widely adopted in
China and abroad, and highlight the principle of "safety for use, reliability of therapeutic
effect, feasibility of processes, controllability of manufacturing quality and perfection of
specification." Volume I of Chinese Pharmacopoeia 2005 contains monographs of
Chinese material medica, including prepared slice, vegetable oil/fat and its extract,
patented Chinese traditional medicines, and single ingredients of Chinese crude drug
preparations. 1,146 monographs are included, with 154 new admissions and 453 revisions.
New scientific methods, such as thin layer chromatography, high performance liquid
chromatography (HPLC) and gas chromatography, are now used as standards of identity
and content. The number of monographs adopting thin layer chromatography as a
standard method to identify and quantify Chinese medicines reaches 1,523; the number of
monographs adopting high performance liquid chromatography as a standard reaches 479;
and the number of monographs adopting gas chromatography in the tests for
identification and content reaches 47. Tests on 12 pesticides containing organic
phosphorous and 3 pesticides containing pyrethroid are added for determination of
pesticide residues. Atomic absorption spectrophotometry or inductively coupled plasma
mass spectrometry is introduced to determine 6 kinds of heavy metals and deleterious
elements, and the limits for lead, cadmium, mercury, arsenic and cupper are stipulated for
the first time.43 Using the above scientific methods for quality assurance is now
collectively called fingerprint technology. It offers significantly improved standards of
quality verification.
Using fingerprints to identify and demonstrate the consistency of herbal materials and
drugs now is accepted by FDA. Chinese SFDA plans to regulate herbal medicine by
fingerprints of the material used, intermediate products and final drugs. Beginning in
2004, fingerprints of liquid injections have been compulsorily carried out. With the help
of fingerprints obtained, the authentication and identification of medical herbs and herbal
medicines can be conducted with reasonable accuracy. Because Chinese medical herbs
and herbal medicines are complex compounds and may contain thousands of chemical
ingredients, the amount and/or concentration of the chemically characteristic constituents
reflected by fingerprints of different samples would not be exactly the same for different
samples. To resolve this problem, fuzzy determination technology is now used to
authenticate the "sameness" of Chinese medical herbs and herbal medicines, such as
fuzzy cluster analysis method 44 . Some Chinese herbal medicines, such as Fufang
Danshen Diwan and Fuzheng Huayu Pieces, have already come under stringent quality
controls using fingerprints, the consistencies of the materials used in these medicinal
formulas that are under the prospective clinical trials approved by the US FDA are
thought to be under reasonable quality control and the variances are within acceptable
ranges.
The second issue with regard to the quality control has to do with the findings that the
43 Preface of the Chinese Pharmacopoeia 2005
44 Fingerprint of Pogostemon cablin by pyrolysis-gas chromatography and its fuzzy cluster analysis, Zhang Mingguang,
et al., Chinese Traditional And Herbal Drugs, 2003 Vol.34 No.8 P.749-752
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therapeutic effects of herbs with the same name may vary significantly if they have
different plant origins, growing conditions, harvest seasons, and drying processes.
According to the concepts of Chinese medicine, Chinese medical herbs have four natures
and five flavors. The four natures are "cold, cool, warm and hot." The five flavors are
"sour, bitter, sweet, spicy/acrid and salty." Herbs with the same name but from different
sources may vary in their nature and flavor, so they should be used differently. Simply
comparing their fingerprints and selecting some commonness as quality control standards
may not be proper in this case. Subdivision according to some determination factors and
using fingerprints for each subdivision are being practiced to provide added quality
control.
The use of fingerprints to identify and measure herbs and mixed formulas has gained
significant footing in developing quality standards in this field and the technologies
included in the fingerprints are proliferating as scientific researches progress. But the
fingerprint technologies are facing major challenges. First of all, since Chinese medicinal
herbs and mixed herbal medicines are holistic systems synergistically constituted by
many ingredients, and many of which are of very low quantities. Even if several markers
or pharmacologically active ingredients can be identified, the best therapeutic effects and
properly controlled toxicity may be obtained only with the cooperation of those
ingredients of very low quantities. So, using fingerprints to authenticate and identify
Chinese medicinal herbs and herbal medicines requires more attention on the holism of
the mixtures., In this aspect, multiple dimensions of fingerprints and fingerprints from
technologies focusing more on the holism of the herbal mixtures and in-depth analysis of
the fingerprints may be needed. Although fingerprints provide scientific aspects of
Chinese herbs and herbal medicines, and may be used as standards to authenticate and
identify different herbs and herbal medicines, the process could be very complex and
holism is a very important consideration. In short, using fingerprints to improve the
quality control and consistency of Chinese herbs and herbal medicines has just been
around for a short time. Good quality and consistency have been obtained in some herbs
and herbal medicines, but not in others. There is still a long way to develop a
comprehensive and credible characterization fingerprinting for Chinese herbs and herbal
medicines. On the Chinese regulator's side, the SFDA has taken steps to standardize
procedures for medical material preparation. Good Agriculture Practice requirement and
qualification standard was issued in November 2003 to regulate the production of
medical herbal materials from perspectives of ecological environment, germplasm and
breeding, cultivation, collection, transportation, packaging and quantitative
administration. By monitoring and standardizing the basic process of Chinese herbal
medicines, the quality of Chinese herbal medicine may improve gradually and steadily.
Those Chinese herbal medicines that have obtained FDA's IND approval to enter clinical
trials, such as Fufang Danshen Diwan, Kanglaite Injection, Fuzheng Huayu Piece and
Guizhi Fuling Jiaonan, have their materials provided by their own herbal planting bases
or suppliers with GAP qualification and under standard operating procedures (SOP). But
because a lot of investments will be needed to systemically update and standardize
operations required by GAP and SOP, GAP qualification is not currently required by
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Chinese SFDA for the time being, so relatively few Chinese pharmaceutical entities or
medical herb planting entities have decided to obtain GAP qualification. Since 2004, only
46 entities with 39 kinds of herbs have obtained GAP qualification.45 The following
chart summarizes these herbal entities:
Time No. of Herbs
entities
March 8 root of red-rooted salvia (danshen), panax notoginseng (sanqi),
2004 cornor (shanzhuyu), cordate houttuynia (yuxingcao), stigma croci
(xihonghua), banlangen, gen-seng, panax
December 10 dwarf lilyturf (maidong), gardenia (zhizi), Artemisia apiacea
2004 (qinghao), poppy shell (yingsuke), Chinese goldthread (huanglian),
cornor (shanzhuyu) (two), panax, creat (chuanxinlian), erigeron
breviscapus (dengzhancao)
June 2005 8 fleece-flower root (heshouwu), pseudostellaria root (taizishen),
balloonflower (jiegeng), root of codonopsis pilosula (dangshen),
coix seed (yiyiren), fiveleaf gynostemma herb (jiaogulan), officinal
dendrobium stem (tiepi shihu), panax notoginseng (sanqi)
February 12 tuber of elevated gastrodia (tianma), cornor (shanzhuyu),
2006 banlangen, catnip (fjingjie), astragalus root (huangqi), cabline
patchouli (guanghuoxiang), rhizome of Sichuan lovage
(chuanxiong), oriental water plantain (zexie), dahurian angelica
(baizhi), corydalis (kudiding), gingko leaf, pseudostellaria root
(taizishen)
December 8 rough gentian (longdan), figwort (xuanshen), glutinous rehmannia
2006 (dihuang), Chinese wam rhizome (shanyao), angelica (danggui),
coltsfoot flower (kuandonghua), polygonum capilalum
(touhualiao), bulb of ussuri fritillary (pingbeimu), panax (dihuang
and shanyao are of one entity)
2.2.4.2 Pre-clinical research - toxicity and pharmacokinetics
FDA requires submitting data showing that the drug is reasonably safe for use in
small-scale clinical trials. To meet the requirement, in vitro or animal studies need to be
performed to collect non-clinical data about safety or submitting data obtained from
previous clinical testing or marketing of the drug in US or other countries which have a
population relevant to that of US.
Unlike western chemical drugs, which are highly targeted on a specific pathway
underlying the disease process, Chinese herbal medicine focuses more on adjusting the
holistic mechanism in the human body, which in turn resumes the body to a healthy
45 Refer to the GAP statements of Chinese SFDA.
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condition. When Chinese medical practitioners use Chinese herbal medicines, they not
only consider the disease condition of the patients, but also the total host conditions as
well as social and psychological factors which may affect the holistic function of human
body's defense system. Consequently, the results of pre-clinical researches of Chinese
herbal medicine, in vitro or in animal models, may not reflect the holistic adjusting
mechanism. For Chinese herbal medicines that aim at preventing chronic diseases or
helping patients with systematic diseases, such as psoriasis, to resume healthy conditions,
it is even harder to design proper in vitro or animal studies.
Various toxicity tests are an important part of pre-clinical research, but often are ignored
in Chinese herbal medicines. Short test time, lacking of standard examination records,
insufficient test index are common problems of toxicity tests of Chinese herbal medicine.
When performing toxicity tests for Chinese herbal medicines, the measurement metrics
are not easily standardized because the unique characteristics of formulation adjustments
according to different syndromes and the cooperative effects among constituent
components. By cooperation, the toxicity of one component may be reduced significantly,
and the therapeutic power may be enhanced. To perform toxicity tests according to
different syndromes of the same disease and on pairs or groups of components may be
more suitable to Chinese herbal medicine. Further, the effective dosages of many Chinese
herbal medicines are too great for administration into animals. This is another obstacle for
pre-clinical research of Chinese herbal medicine. The newly developed micro-powder
and ultra fine-powder technology, which breaks the herbal cell walls and helps release
effective components, may help to greatly improve the utilization ratio of Chinese herbal
medicines so as to reduce the effective dosage. Unlike western chemical drugs, which
usually have only one action target, Chinese herbal medicines usually have multiple
action targets. Toxicity may accumulate over a long-term use and may not be
discoverable through acute toxicity tests. Therefore, toxicity tests of Chinese herbal
medicines require more careful analysis. From various reports, an important cause of the
toxicity problems of Chinese herbal medicines is improper use; many patients obtain
herbal medicine preparations without consulting doctors because no medical prescription
is required. General education on proper use of Chinese medicine would likely reduce
these problems.
In terms of pharmacokinetics studies, the challenge is very obvious. Since Chinese herbal
medicines usually contain many ingredients, many of which are still unknown, it is
difficult for pharmacokinetics studies to obtain a complete understanding of Chinese
herbal medicine. Currently, the serum-pharmacology of compounds provides a valuable
academic base for pharmacokinetics studies of Chinese herbal medicines. Other new
research methods are also under active exploration.
It is expected that as more pharmaceutical entities are GAP qualified, the quality and
consistency of materials will improve greatly. Coupled with new methods and
technologies, this will provide a solid base to control toxicity and pharmacokinetics
studies for Chinese medicines. As part of the overall drug quality control efforts, in
December 1997, Chinese SFDA issued Good Laboratory Practice for Non-Clinical
Laboratory Studies (GLP) to regulate the non-clinical laboratory studies for all the drugs
in China. After two revisions, the newest edition of GLP was issued in 2007, providing a
system to regulate the design, operation, recording, report and data audits of non-clinical
research. According to GLP, detailed standards are essential for each process that could
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affect the validity and integrity of the final result.
Since the regulation is relatively new, only very few institutions have applied and
obtained GLP certification. The following are basic statistics: 46
Year 2003 2004 2005 2006 2007 Total
No. of Entities (GCP Qualification) 4 7 4 8 3 26
With the improvement in material quality control and consistency, some pre-clinical
researches of Chinese herbal medicines have met the requirements of FDA. Although
these examples are scarce in number as statistics have provided in the previous sections,
the overall trajectory of increased FDA compliance is very encouraging.
2.2.4.3 Clinical trials - design and efficacy evaluation
In 1985, regulations about clinical trials of Chinese herbal medicine appeared in China
for the first time. In 1998, Good Clinical Practice for Drugs was issued, and herbal
medicines were under the regulation. Chinese SFDA required that all institutions
conducting clinical trials and medical institutions involved in drug clinical researches
should obtain GCP qualification and perform their investigative duties, to effectively and
responsively manage and coordinate clinical trials, to ensure that their researches are
conducted in accordance with relevant laws and regulations, to ensure that the quality of
drug clinical research and reliability of research data and protect the interests of testing
subjects. By the end of 2005, 93 institutions obtained GCP qualifications. In 2006, 65
more institutions became GCP qualified 47. Conducting thousands of active ongoing
clinical trials in Chinese medicines, the 158 institutions with GCP qualification are by far
in short supply. Conceivably, it is really difficult for these GCP qualified institutions to
perform high quality and sufficient clinical trials under such a heavy workload.
How to design a scientific clinical trial for Chinese herbal medicines impose a big
problem, for few practitioners who understand well the medicines to be tested have
sufficient knowledge about scientific clinical trials, while those who know how to design
and perform scientific clinical trials seldom understand the special characteristics of
Chinese herbal medicine. For example, Chinese herbal medicines, which are aimed at
restoring patients to healthy conditions through adjusting basic accommodation or
compensatory mechanisms in the human body, usually have multiple action targets and
may be suitable for several disease processes. As a consequence, the criteria for inclusion
and exclusion are usually not as stringent. In terms of controls, clinical trials of Chinese
herbal medicines often use other herbal medicines perceived to have positive effects as
controls, rather than placebo. Since the perceived positive effects of the control
medicine(s) used as controls lack solid confirmation or objective measurement criteria,
false positive problem imposes a big issue for such trials and reduces the credibility and
reliability of the results. As the preparations of Chinese medicines become miniaturized
or formulations capsulated, it becomes possible to use placebo and this control issue in
the trial design can be resolved. With regard to objective measurable endpoints in the
46 Refer to the GLP statements of Chinese SFDA.
47 According to the GCP qualification statements issued by Chinese SFDA.
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clinical trials, scientifically verifiable standardized tests various well accepted scientific
methods are becoming commonplace in clinical trials of Chinese herbal medicine, which
help improve the quality and credibility of the trials. For example, in the clinical trials of
Fuzheng Huayu Piece (Chinese medicine for liver disease) performed in China, Golden
standard of liver biopsy was used to measure the endpoints and newest version of
statistical analysis software suggested by FDA are used, which facilitate FDA to
understand the documents about the trials and increase the reliability of the results.
From the US FDA's perspective, the biggest problem of clinical trials of Chinese herbal
medicines is the evaluation and proof of efficacy. Current efficacy evaluation methods
and standards generally accepted by FDA usually derive from research on western
chemical drugs, focusing on the changes in pathology and physiology. Chinese herbal
medicines act against a complex set of mechanisms with certain subjective syndromes
rather than specific diseases, with the purpose of resuming patients to a healthy condition
through multiple action targets, systematically adjusting and rebalancing various
mechanisms in the human body. The process tends to be long, and the adjustment
happens gradually. The advantage is that the efficacy effect usually continues for a longer
time than that of western chemical drugs. To address this systematic difference of causal
relationship and underlying mechanisms, on the one hand, companies are attempting to
adjust formulations of Chinese herbal medicines to focus their direct actions on specific
diseases so that the outcomes are more visible and verifiable in a relatively short period
of time. For example, the clinical trials of Kanglaite Injection focus on testing its efficacy
on cancer of pancreas although its original use is to act against multiple kinds of cancers.
The clinical trials of Fuzheng Huayu Piece highlight its effects against liver fibrosis
which is easy to measure through liver biopsy. On the other hand, new evaluation
methods suitable to Chinese herbal medicine are being developed. These efforts focus on
identifying some in-process indexes, such as immunological tests, to evaluate the efficacy
of Chinese herbal medicines when they gradually improving the health condition of
patients. Other evidences, such as changes of tongue and pulse, also play an important
role in the therapeutic processes of Chinese medicine, but the significance of these data
would translate very poorly across cultural boundaries, particularly for those people who
do not have a good understanding of the theories of Chinese medicine. Although since
1997, there have been several kinds of Chinese herbal medicines that received FDA's
IND approval to enter phase II clinical trials, a good sign of improvement of material
quality control, no one has achieved substantial progress as of yet. Efficacy evaluation
has been a major obstacle.
2.2.4.4 Manufacturing quality control
Since 1988, Chinese SFDA has been regulating drug manufacturing by Good
Manufacturing Practice standards. SFDA requires that all pharmaceutical entities
involved in herbal medicine manufacturing should obtain GMP qualification before
January 1, 2008. But until now, only 355 entities in herbal medicine manufacturing have
obtained the qualification while the total number of pharmaceutical entities registered in
herbal medicine manufacturing is more than 1,100. Part of the reasons of the slow
progress is lack of necessary financial resources to overhaul the current manufacturing
facilities to conform the GMP standards. At this time, many herbal medicines
manufactured by unqualified entities are on the market and competing with those
medicines from GMP qualified manufacturers at low prices. The following is a time
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series chart that captures the incremental increase of numbers of GMP certified
manufacturers: 48
Year No. of Entities (GMP No. of Entities (Herbal Medicine)
Qualification) (GMP Qualification)
1999 110 1
2000 596 2
2001 449 1
2002 (584 4
2003 1180 28
2004 2700 74
2005 2165 91
2006 1610 97
2007 1029 57
Total 10523 355
In summary, the Chinese GMP requirements are likely to further raise the overall
competence of manufacturers of Chinese herbal medicines toward FDA quality
compliance. There has indeed been significant progress in this area and it is anticipated
that by 2008, those manufacturers without GMP qualification will be forced out of the
market.
2.2.5 Fingerprint technologies and quality control of Chinese
herbal medicine
Quality control of Chinese herbal medicine is more difficult than that of chemical drugs
because there are multiple ingredients or compounds, many of which are still unknown.
These ingredients are not simply mixed with each other, but synergistically constitute a
therapeutic system.
Fingerprints can provide much important and relevant information about the
characteristics of their constituent chemical compounds, such as its major components
and properties. With the help of separation technology and various scientific analytical
tools, fingerprints now play an important role in authentication, identification and quality
control of herbal medicines. Most significantly, the US FDA has started to accept tests
utilizing fingerprint-related technologies.
Common fingerprint related technologies include thin layer chromatography (TLC), gas
chromatography (GC), high-performance liquid chromatography (HPLC), high
performance capillary electrophoresis (HPCE), UV spectroscopy, infrared radiation (IR)
spectroscopy, nuclear magnetic resonance, mass spectroscopy (MS), DNA fingerprint,
48 According to the GMP qualification statements issued by Chinese SFDA.
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and the list is growing. Hyphenation technologies, such as HPLC-MS, HPLC-NMR, and
GC-MS, can be used to improve the analytical results. The following paragraphs
highlight some of the major fingerprint methods.
Thin layer chromatography, a classic fingerprint technology, was used by Japanese
researchers on analyzing herbal medicine in the 1960s. The advantages of TLC include
high velocity, versatility, simple sample preparation and good reproducibility. With the
help of image analysis and digitalized computer-aid technique, similarities between
different samples can be evaluated.
Gas chromatography (GC) is very suitable to analyze volatile compounds of herbal
medicines. The prominent advantage of GC is its high effectiveness and high sensitivity
when detecting volatile chemical compounds. Besides that, its high selectivity of
capillary columns enables separation of many volatile compounds simultaneously in short
periods of times.
High-performance liquid chromatography (HPLC) is easy to learn and use, and is able to
analyze almost all the known compounds in herbal medicines at high speed with high
separation capability. So it becomes a very popular method of herbal medicine analysis.
UV spectroscopy can be used to measure the wavelength and intensity of absorption of
ultraviolet and visible light by herbal medicines, but it is more suitable for single
substances. When UV spectroscopy is used to test complex herbal compounds, the results
should be backed up by HPLC.
The processes of using fingerprints as quality control for herbal medicine include
fingerprint profile establishment, fingerprint analysis, and using standard fingerprints to
control quality. The following paragraphs describe its general process.
The first step is to standardize the extraction process of Chinese herbal medicine to
produce characteristic samples for fingerprint profile establishment. Then use
chromatography and/or spectroscopy technologies to analyze the holistic extract,
establish fingerprints and identify characteristic data. When standardizing the extraction
process, various factors that affect the consistency of the herbs or the herbal medicines
should be considered. To capture the holistic characteristics of Chinese herbal medicines,
it is better to establish fingerprints that capture most ingredients, but as more ingredients
are included, the more difficult to analyze the established fingerprint profiles. To partially
resolve this issue, multi-dimensional fingerprints may be employed to provide a better
view.
After the fingerprint for the holistic extract is established, the characteristic peaks of the
extract should be analyzed, and then separated into multiple relatively simpler
sub-systems. Sub-systems consisted of pairs or groups of ingredients may be more
suitable to Chinese herbal medicines. Then as the relationship between each sub-system
and characteristic peaks in fingerprint, the therapeutic effects of each sub-system and the
relationship among sub-systems may be correlated and analyzed. Once the characteristics
of sub-systems are identified, repeatability should be examined. Chinese medical theories
should be referred to in analyzing the interrelationships between these sub-systems. When
the above research is finished, the standardized fingerprint for holistic extract and the
characteristics of sub-systems can be used to control the quality of the medical herbs or
the preparation of herbal medicines in accordance with scientific comparability criteria.
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The first Chinese herbal medicine that obtained FDA's IND approval, Fufang Danshen
Diwan, provides a good example of using fingerprints to improve the quality and
consistency of Chinese herbal medicines. Three medical herbs are used to prepare the
drug, which are salvia miltiorrhiza (danshen), panax notoginseng (sanqi), and
cinnamomumn camphora (bingpian). After fingerprint analysis, 10 water-soluble
ingredients of danshen, 20 saponin ingredients of sanqi and their fingerprint
characteristics are identified. Then multiple-fingerprint computation and analysis
technology is used to control the material, the in-process extracts and the prepared
medicine. The results are that the comparability of the materials provided by its GAP
qualified planting base is controlled at levels higher than 95%, the comparability of the
in-process extract and the comparability of the prepared medicines are controlled at levels
higher than 90%. Quality and consistency of the medicines are greatly improved.49
In summary, the development and employment of various fingerprint technologies have
provided new scientific ways to control the quality and navigate the properties of the
whole plants or whole Chinese medicinal formulas. Different from the commonly used
characterization methods to isolate and identify small molecule chemical entities, the
fingerprinting technologies provide insights of the herbal medicines without breaking it
down to many smaller molecules, making it possible to use fingerprints to characterize
and control the properties of herbal medicines in a holistic fashion, consistent with the
intrinsic philosophies of traditional Chinese medicine. With these new technologies, it is
reasonable to foresee that more medicines based on Chinese herbal medicines and a
wealth of accumulative empirical therapeutic medical formulas may be developed in
much less expensive ways and in shorter periods of development times. This alternative
pathway discussed in this thesis, that is, the mixed formula pathway for new drug
development, may serve as a potential solution to today's escalating pharmaceutical costs,
better treatments for hard-to-treat or chronic illnesses, prevention of diseases,
improvement on human beings health status or quality of life and partially relieve
pressure of the US health care "crisis."
2.3 Value Formation from Public Domain Knowledge to
Private Property - Analysis of Literatures and Patents on
Chinese Herbal Medicine
2.3.1 Introduction
The main hypothesis of this thesis is to postulate that there is significant latent value that
has been accumulated about medicines and drugs (including Chinese herbal medicine) in
China and around the world. Many successful drug developments based on Chinese herbs,
including the three case studies in this thesis, have capitalized on the public domain
knowledge in the form of published literature. The patents, in a market economy, are
fundamental to economic value creation 50 . This situation is particularly true in the
pharmaceutical industry. The following sections represent the author's research efforts to
49 Multiple-fingerprint tests for Fufang Danshen Diwan manufactured by Tasly Group
50 Patent Statistics as Economic Indicators: A Survey, Zvi Griliches (1990)
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navigate, summarize and analyze the relevant data to substantiate, at a macro level, the
existence of knowledge and value accumulation through the proliferation of scientific
literatures and patents regarding Chinese herbal medicine. This public and private
knowledge would form a new paradigm from which values may be created and captured.
Patent analysis is an important topic in the management of technology. Academics and
corporations acquire information of technological development and competitive
intelligence from patent database. The number of patents issued is often a surrogate
indicator of technological R&D output. The simplest way to measure R&D productivity
is to count the number of patents. Griliches (1990)51 indicates additional insight into
patents. Patents not only can measure inventive activities in the way of output but also as
input. In other words, patent statistics can act as economic indicators. Furthermore, patent
statistics are also technological indicators by improving patent information to judge
technological change (Basberg, 1987)52. One can transfer patent data into valuable
information or into intelligence by patent analysis. Usually, patent analysis has two
purposes for general use: competitive analysis and technology trend analysis (Liu & Shyu,
1997)53.
A patent is a document, issued by an authorized governmental agency, granting the right
to exclude anyone else from the production or use of a specific new entity, device,
apparatus, or process for a stated number of years. The grant is issued to the inventor of
this entity or process after an examination that focuses on both the novelty of the claimed
item and its potential utility. The right embedded in the patent can be assigned by the
inventor to somebody else, usually to his employer, a corporation, and/or sold to or
licensed for use by somebody else. This right can be enforced only by the potential threat
of or an actual suit in the courts for infringement damages. The stated purpose of the
patent system is to encourage invention and technical progress both by providing a
temporary monopoly for the inventor and by forcing the early disclosure of the
information necessary for the production of this item or the operation of the new process.
Kuei-Kuei Lai, Mei-Lan Lin, and Shu-Min Chang (2006)54 defines patent analysis as
methods for analyzing patent data. The standard for patent analysis appears to be similar
across the globe, all industries, and all companies. Basber (1987)5 synthesizes earlier
patent literature into three types. One type relates to the legislation and the functioning of
the patent system. The other two are rationale of the system and patent as technical
information. Regarding the third type, he also points out three groups of patent statistics
as technology indicators. Patent analysis in strategic planning is dissected on the
propensity of innovative activities, and the research trajectories between science and
51 Patent Statistics as Economic Indicators: A Survey, Zvi Griliches (1990)
52 Patent and the measurement of technological change: a survey of the literature, Basberg, B.L. (1987)
53Strategic planning for technology development with patent analysis, Liu, S.J. and Shyu, J (1997)
5 Research Trends on Patent Analysis: An Analysis of the Research Published in Library's Electronic Databases,
Kuei-Kuei Lai, Mei-Lan Lin, Shu-Min Chang (2006)
55 Patent and the measurement of technological change: a survey of the literature, Basberg, B.L. (1987)
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technology (Pavitt, 1985)56. Tsuji (2001) 5 7 systematically classifies literatures of patent
analysis into three groups. The first group is international comparison. The others are
econometric analysis and technology changes. In addition, using patent statistics as
indicators of innovative activities are based on three perspectives of economics,
bibliometrics, and descriptive comparisons for policy uses. Besides, Ernst (2003)58
recommends the value of patent information for strategic planning, and he has built a
conceptual framework showing patent function in technology management. Patent
information is a useful source in five areas. Patent analysis can be employed in
competition monitoring, assessing the attractiveness of technologies, technology portfolio
management, the identification of external sources for knowledge generation, and human
resource management. Similarly, many researches exemplify numerous methods of
applying patent analysis, especially in technology competition analysis, investment
evaluation, patent portfolio management, research management, product scope
surveillance, corporate valuation, as well as mergers and acquisitions. 59 In the same way,
the published literature could also be a source to analyze the accumulation of public
domain knowledge, which, in turn, may be the sources to cultivate production of new
patents.
For this thesis, I have collected and attempted to analyze literatures and patents that are
related or possibly related to Chinese herbal medicine.
2.3.2 Methodology
All data I used is from creditable sources.
The Chinese patent data is from SIPO database (http://www.siop.gov.con)
The world patent data is from LexisNexis (https://www.lexisnexis.com), the database is
US Patents, European Patents, Patent Abstracts of Japan, PCT Patents, and UK.
The world patent data is also from Derwent innovations index
(http://portal.isiknowledge.com), the database is Chemical--1963-present, Electrical and
Electronic-- 1963-present, Engineering-- 1963-present.
The Chinese literature data is from CNKI (http://www.edu.cnki.net)
The worldwide literature data is from ISI Web of Knowledge /medicine
(http://portal.isiknowledge.com/), the database is In-Process and
MEDLINE--1950-present
Some data is from China Science & Technology statistics data book
(http://www.sts.org.cn/sikl/kitjdt/index.htm)
Some data and analysis is from the literature that I cited, and I will explain in the
56 Patent statistics as indicators of innovative activities: possibilities and problems, Pavitt, K. (1985)
57 A Methodological Study of Patent Statistics for Technoeconomic Analysis, Tsuji, Y.S. (2001)
58 Patent information for strategic technology management, Ernst, H. (2003)
59 Using patent information in technology business planning. Breitzman, A.F. and M.E. Mogee (2002). The many
applications of patent analysis, Ashton, W.B. and Sen, R.K. (1988)
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paragraph why I use this data.
First, I will use the data to describe how many literatures or patents I found, and then I
will compare different types of literatures or patents. Then, lay out the data along the time
vector to see the change of numbers over time.
For literature analysis, similar keywords are used to search the literature by year.
Keywords used are as following:
CNKI:
TS= •j and WR
TS=I E and ••~i
TS=I 45 and WM
TS= I4 and -Jf
TS= i9 and $1J A
TS=AM and 5M
TS=AiK and 40 --K
TS=AiK and OIMM:
TS=IFR and I*&)ý
TS=9 A, and WIL/5'M
TS=F M and -T--f
ISI:
TS=Drug or TS=medicine and TS=general
TS=Extractions
TS=Purification
TS=Synthesize
TS=Manufacturing
TS=Experiments
TS=Animal Experiments
TS=Human Clinical Trials
TS=New formulations
TS=Novel compounds
TS=Molecular mechanisms
- 73 -
As we can see from the above keywords which may be potentially related to medicine or
drugs, but may not be specifically related to Chinese herbal medicine. This is for two
reasons, one, I found it to be hard to design keyword search profiles specifically for
Chinese herbal medicine, two, I would rather characterize the overall innovative activity
in drug development rather than just the Chinese herbal medicine, since most of the latter
have been integrated into the overall scientific activities of drug development. It is
relevant to this thesis to sense the level of activities and also the general ability to
translate public domain knowledge into private intellectual properties and the implicit
ability as an economy to capitalize on the latent knowledge value.
2.3.3 Analysis of literature statistics
According to S&T papers of selected countries catalogued by SCI, EI and ISTP as a
whole and by SCI, China ranks the 4th among all the countries in terms of the number of
papers. The number of papers issued by SCI. EI and ISTP is 153,374. At the same time, the
US ranks the 1st and the number of papers is 666,360. Papers from China may be close to
the UK and Japan, but it is still a great gap to US.60 From 2000 to 2006, literatures
relevant to medicine published in China are increasing but the rate is far more behind
those in the economically developed world. (CNKI database' update in 2006 is not yet
complete at the time of search.) The data is tabulated and shown as attachment 1 of this
thesis.
As the following charts will collectively show (most charts are for illustration purposes
and self-evident; narrative explanations and units are omitted), although the literatures
published in China about extractions is close to the total in the world, the major
differences are in the later processes of drug development. In areas such as "purification,"
"synthesization," "manufacturing," "experiments," and "new formulations," China is
significantly and often by far behind the English-language world.
60 From: http://www.sts.org.cn/sikll/ktidt/data2006/2006-6.htm
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Figure 2.3.7: Search results of "new formulations" of CNKI and ISI
2.3.4 Patent statistics
As a general context, as shown in the figure 8 as follows, China's R&D investments
increase quickly in recent years, but are still far behind those in the US.
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* GERD Gross Domestic Expenditure on R&D
61 From: http://lwww.sts.org.cn/sikl/kitidt/data2006/2006- 1.htm
62 From: htto://www.sts.ore.cn/sikl/kitidt/data2006/2006-6.htm
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Both patent applications and patents granted related to medicines increased quickly from
1995 to 2003. (Please refer to Attachment 2 and 3 about the tabulated results of the
searches.)
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Figure 2.3.10: The three types of medicinal patent application from 1995-200363
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Figure 2.3.11: The three types of medicinal patent granted from 1995-200364
63 Chinese patent data, search results from SIPO database
64 Chinese patent data, search results from SIPO database
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In the published articles, some authors argue that the contribution of patents to the GDP in
China is not obvious in China, because of the absent of strong IP law or lack of
enforcements for IP rights. But the effects of patents will likely increase as the legal and
regulatory system in China becomes more mature in the future. In China, as the search data
shows, nearly half of the medicinal patent applications were foreign applications. The
applications of patents regarding botanic drugs (herbal medicines) and drug compounds as
well as methods for production constitute the vast majority.
The above data, by and large in a qualitative fashion, demonstrates that there is a
significant body of published knowledge and steadily growth of patent applications and
issuance. The published Chinese language knowledge as scientific articles, in the
keyword searches related directly and indirectly to medicines, is largely corresponding to
the earlier and general categories of drug development rather than the keywords of
"purification," "synthesization," "manufacturing," "experiments," and "new
formulations" that are categorically corresponding to later stages of drug development
pathways. In the patents filed in the Chinese patent agencies, a significant portion of
applications and grants are those that originated in foreign countries. Many
manufacturing and process patents are filed by Chinese domestic applicants. Taken
altogether, the data supports the hypothesis that there is early formation and quick growth
of scientific knowledge and IP, an indicator for latent valued to be realized and captured
as time progresses.
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3. Case Studies
Among the singleton pathway and the alternative mixed formula pathway, the former is by
far the most commonly used drug development trajectory from herb (plant) sources so far.
In this section, I present three different case studies. The purpose of these case studies is to
delineate the critical pathways, both from scientific and regulatory perspectives that the
developers followed or are following. These cases are drugs targeting the anti-diabetic
market and in different development stages, the drug Metformin (Glucophage) was derived
from a plant known as French Lilac; the compound PGG and its derivatives are originated
from the banaba plant (lagerstroemia speciosa), and some of the materials are from my
personal communications with the developer, Professor Xiaozhuo Chen at Ohio
University, who has graciously agreed to allow me to use the development story and data
in this thesis. The development efforts are still underway, and the compound resveratrol,
which was originally isolated from grape skin, is now known to exist in many plants. A
new company founded by several Harvard Medical School professors is attempting to
commercialize the compound and its derivatives as anti-diabetic drugs for FDA approval.
Common to all three cases, a wealth of empirical therapeutic evidence and published
articles precedes the patenting and commercial development activities. In other words,
the common trajectory appears to be a time series transformation from empirical
experience into scientific research and publications and then into formation of private
intellectual properties which further drive the commercialization. This common trajectory
indirectly supports this thesis' hypothesis that value may be created from the accumulated
knowledge in Chinese herbal medicine.
From the scientific perspective, all these three cases involve extraction and isolation of
therapeutically effective compounds, molecular characterization, purification and
modification, and sometimes synthesizations.
3.1 Metformin
3.1.1 Introduction
The reason of my selecting this case study for the thesis is the winding but successful road
taken by innovative scientists and by several pharmaceutical companies in converting a
plant with a long history of empirical evidence of therapeutic benefits into an ethical drug.
The story delineates the processes of scientific discoveries and persistent efforts on the part
of various pharmaceutical companies to satisfy FDA's rigorous requirements on
controlling adverse effects caused by this herb-derived drug. This success story, as my data
on the published literature and patent applications/grants, has sparked continued interests
to further improve the existing drug or discover new drugs with fewer side effects.
Metformin is an oral anti-diabetic originally derived from the plant French Lilac, standing
the test of time and continuing to be an important component in the management of
diabetes. The following chart correlates the scientific discoveries about insulin and
metformin with the major technological breakthroughs in history65. For example, the first
65 Understanding RTK signaling specificity: insulin versus IGFs, Pierre DeMeyts
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insulin crystal was created in 1926 which coincides with Lindberg's cross-Atlantic flight,
discovery of Metformin in 1957 which coincides with the launch of the Sputnik Satellite.
These seemingly unrelated events may not be coincidental after all, because scientific
values may not be realizable unless the human being has acquired enough body of
knowledge and produced a high enough level of technological know-how.
Figure 3.1.1 Scientific discoveries about insulin and metformin with the major
technological breakthroughs in history66FistpesoalCopuerFistinuln naoge
NH NH
H3 C9N N NH
I H
CH3
Figure 3.1.2 Chemical structure of Metformin 67
66 Understanding RTK signaling specificity: insulin versus IGFs, Pierre DeMeyts
67 www.3dchem.com & http://pl.wikipedia.org/wiki/Metformina
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Chemical formula of metformin is C4HllN 5. Metformin targets the liver, and has
secondary effects on muscle and fat. The main actions of metformin include lower
glucose production by the liver, increased number of insulin receptors on muscle and fat
cells and lowers HbAlc by 1.5% to 2.0%. Main side effects include bloating, fullness,
nausea, cramping, diarrhea, vitamin B12 deficiency, headache, metallic taste, agitation,
and occasionally lactic acidosis.
Action mechanism of metformin is illustrated in the following diagraph:
Figure 3.1.3 Mechanism of metformin68
Metformin is the only example of an approved anti-diabetic drug that was developed
from an herbal source with a long history of use for diabetes. On March 3, 1995,
Glucophage (active ingredient is metformin hydrochloride) obtained FDA approval (NDA
020357). In 1996 Glucophage became the largest selling oral anti-diabetic agent in the
world. It is also the top-selling French drug in the US. Around eight million patients in
more than 100 countries worldwide benefit from Glucophage (metformin).69
3.1.2 Development history of metformin
Metformin is derived from French lilac plant, which was noted in the early 1900's to lower
blood sugar. Diabetes has been a mysterious disease for very long period of time. It took
centuries to identify its mellitus form and its ties to insulin came to be known even much
later. The ultimate acceptance of the biguanides and the understanding of their mechanism
of action is part of contemporary history. Prior to the availability of insulin and
68httn:/musik~mvweh~iga~eduI/2ntidih2. hi-m
69 http://www.ezeediabetes.co.za/co-owelgl ucstory.asp
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anti-diabetic medicines, hypoglycemic plants (400+) were extensively used throughout the
world. 70 The most interesting one was galega officinalis (also known as goat's rue,
French lilac, Italian fitch or professor-weed), a plant from the Galega genus of the
Faboideae, found to yield akaloid galegine.
Figure 3.1.4 The plant French lilac7'
The therapeutic effects of French lilac have been known in the folk population for a long
time. In medieval times, a prescription of French lilac was able to relieve the intense
urination accompanying the disease that later known as diabetes mellitus. French lilac
was also given during plague epidemics to promote perspiration and has been used as a
galactogogue in cows. The active ingredient in the French lilac that produced the
hypoglycaemic effects was shown to be galegine or isoamylene guanidine. A curious
chapter in the history of guanidine-based hypoglycemic agents arose from the mistaken
notion that the tetany of hypoparathyroidism was due to over production of guanidine
following parathyroidectomy, leading to the demonstration that an infusion of guanidine
produced lowering of blood glucose.72
In the early 1900's, the pharmacological and therapeutic properties of French lilac led to
the use of guanidine derivatives in the treatment of diabetes mellitus. Galegine was
isolated as an active anti-hyperglycemic agent from the plant galega officinalis 1, which
became the template for the synthesis of metformin and the synthesis of other
biguanidine-type anti-diabetic drugs.
70 The Story of Glucophage
71 The blooming of the French lilac & http://commons.wikimedia.org
72 The blooming of the French lilac
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Figure 3.1.5 The synthesis of metformin and other biguanidine-type anti-diabetic drugs73
Watanabe first noted the hypoglycemic effects of guanidines at the beginning of this
century. Since guanidine was quite toxic, substituted guanidines (synthalin A and B) were
synthesized around 1928 and utilized, which turned out to be very toxic as well. This led
to the synthesis of biguanides in 1929. However, some initial investigators believed even
the most active of these biguanides (NI, N1-dimethylbiguanide or metformin) to be not
indicated for use as an insulin substitute in humans. Phenformin (phenylethylbiguanide)
was synthesized in 1956.74 The breakthrough of metformin, a dimethylbiguanide, was
made possible by Jean Sterne (1919-1997), a French physician and pharmacologist, in the
mid-1950s.75
In 1955, Hollunger and Creutzfeld pinpointed the mechanism of action of the guanidines
through pharmacological and pathological studies. Dr. Jean Sterne and his colleague
Denis Duval of Aron Laboratories near Paris, screened hypoglycaemic actions and
degrees of toxicity of different biguanide compounds in 1956, and eventually chose
metformin (dimethyl-biguanide hydrochloride) since it showed the greatest efficacy for
the lowest toxicity. Their metformin preparation was branded "Glucophage." The first
clinical trials using Glucophage were conducted in 1957. The clinical trials showed that
the effectiveness of Glucophage increased with age and degree of obesity and the product
was "surprisingly safe." By the end of 1965 in France, Aron Laboratories' factory
produced about 12 tons per year. In 1982, Jan Aron sold 75% of his company to Lipha,
who provided the necessary additional capital, technical tools and marketing capacity
required. The Aron takeover by Lipha and research into the complexity of insulin
resistance ushered in a new era for metformin. Metformin made its final breakthrough
when clinical research studies established the link between hyperinsulinism (elevated
insulin levels) and obesity. Lipha grew to become Groupe Lipha in 1987. In 1973,
metformin was approved to be sold in the German market. For the US market, the story is
very winding:, among the two drugs from the biguanide class, metformin and phenformin,
the drug phenformin was introduced in the US market first under the names D.B.I.,
Meltrol-50 capsules in 1970, but phenformin was associated with a life-threatening side
73 The Value of Plants Used in Traditional Medicine for Drug Discovery, Daniel S. Fabricant and Norman R. Farnsworth,
Environ Health Perspect 109(suppl 1) :69-75 (2001).
74 Medical Officer Safety Review, Epidemiology & Clinical Trials Branch, Metformin
75 Metformin: The Long Path to Success
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effect of lactic acidosis, and was withdrawn from the US market on November 15, 1978.76
When this risk surfaced, phenformin was pulled from drugstore shelves worldwide.
Metformin was eventually found to be 20 times less likely to cause lactic acidosis, but it
was tainted by the history of its cousin. It was not cleared for use in type 2 diabetes in the
US until 1994.77 Lipha's application file to the FDA to market metformin in the US
market is the "thickest" file ever presented in the US: 412 volumes of about 400 pages
each - a total of 165,000 pages. The file contained a full thirty-five years of European
toxicology and therapeutic experience including 2,000 publications and the summaries of
100 clinical studies. It cost Lipha over $60 million. Lipha subsequently selected
Bristol-Myers Squibb (BMS) as their American partner.78 On March 3, 1995, BMS'
Glucophage (active ingredient is metformin hydrochloride) received FDA approval (NDA
020357).
The approval history for Glucophage (NDA 020357) is summarized as follows: 79
Action Date Supplement Number Approval Type
03/03/1995 000 Approval
09/13/1995 002 Package Change
04/30/1996 003 Control Supplement
07/26/1996 004 Manufacturing Change or Addition
06/06/1997 005 Manufacturing Change or Addition
11/06/1997 006 Labeling Revision
02/10/1998 008 Labeling Revision
05/15/1998 007 Manufacturing Change or Addition
07/02/1998 009 Manufacturing Change or Addition
10/22/1998 010 New or Modified Indication
11/05/1998 011 Formulation Revision
11/18/1998 013 Manufacturing Change or Addition
12/04/1998 014 Control Supplement
03/12/1999 016 Manufacturing Change or Addition
06/01/1999 015 Manufacturing Change or Addition
06/07/1999 018 Control Supplement
09/22/1999 017 Efficacy Supplement with Supporting
Clinical Data
08/04/2000 021 Manufacturing Change or Addition
76 Controlling Diabetes with Class, David Mendosa,
77 http:llwww.diabetesnet.com/diabetes treatments/metformin.php
78 The Story of Glucophage
79 Drugs@FDA
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12/15/2000 019 Patient Population Altered
02/08/2001 022 Labeling Revision
04/19/2001 020 Efficacy Supplement with Supporting
Clinical Data
01/08/2002 024 Labeling Revision
03/19/2004 026 Labeling Revision
03/19/2004 027 Labeling Revision
11/01/2006 030 Labeling Revision
3.1.3 Initial success, new insights and continued research
Success stories always ignite people's interests to further navigate the underlying
mechanisms and look for new insights, which may lead to discovery of other new or
improved drugs. The side effects of Metformin have also been a source of academic and
commercial interests.
The drug metformin is an effective treatment for NIDDM (non-insulin dependent
diabetes mellitus) which accounts for 90-95% of the total number of patients with
diabetes mellitus. An estimated 12 million people in the United States have NIDDM.
Patients with NIDDM nearly always have both insulin resistance and abnormal pancreatic
beta-cell function. Metformin has increased glucose disposal in most studies using
hyperinsulinemic-, euglycemic-, and hyperglycemic-clamp procedures in patients with
NIDDM, with muscle implicated as its main site of action.
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Figure 3.1.6 Dynamic mechanisms of NIDDM and of the drug metformins8
Table 3.1.1: Pharmacokinetic Aspects of Metformin 81
VARIABLE COMMENT
Bioavailability 50-60 percent; absorbed mainly from the small intestine;
estimated absorption half-life, 0.9 to 2.6 hours
Plasma concentration Maximal, 1 to2 jig per milliliter (approximately 10-5 M) 1 to 2
hours after an oral dose of 500 to 1000 mg, negligible binding to
plasma proteins
so http://www.jewJishhospitalcincinnati.com/cholesterollimages/current diabetes reports-GD-figure.gif
81 Metformin, Clifford J. Bailey, Ph.D., M.R.C.Path., and Robert C. Turner, M.D.
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Plasma half-life Estimated at 1.5 to 4.9 hours
Metabolism Not measurably metabolized
Elimination About 90 percent is eliminated in urine in 12 hours;
multi-exponential pattern involving glomerular filtration and
tubular secretion
Tissue distribution Distributed most tissues at concentrations similar to those in
peripheral plasma; higher concentrations in liver and kidney;
highest concentrations in salivary glands and intestinal wall
Table 3.1.2: Mechanisms of the Antihyperglycemic Effect of Metformin 82
MECHANISM COMMENT
Suppression of hepatic glucose Contributes post-absorptive and postprandial
output plasma glucose -lowering effect
Increased insulin-mediated Demonstrated by glucose -clamp procedures; due at
glucose disposal least in part to a reduction in blood glucose
concentrations
Increased intestinal glucose use Shown only in studies in animals
Decreased fatty-acid oxidation --
Table 3.1.3: Clinical Use of Metformin 83
VARIABLE COMMENT
Type of therapy Monotherapy; combination therapy with a sulfonylurea
Indications After failure of dietary therapy in N1DDM, especially in over
weight patients; after failure to achieve acceptable glycemic control
with sulfonylurea therapy
Tablet sizes 500 mg; 850 mg
Treatment Should be taken with meals; dose should be increased slowly;
schedule maximal dose, 2,550 mg daily
Contraindications Renal and hepatic disease; cardiac or respiratory insufficiency; any
hypoxic condition; severe infection; alcohol abuse; history of lactic
acidosis; use of intravenous radiographic contrast agents;
pregnancy
82 Metformin, Clifford J. Bailey, Ph.D., M.R.C.Path., and Robert C. Turner, M.D.
83 Metformin, Clifford J. Bailey, Ph.D., M.R.C.Path., and Robert C. Turner, M.D.
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Side effects Gastrointestinal symptoms (diarrhea, nausea, abdominal
discomfort, anorexia) and metallic taste, which improve with dose
reduction; may impair absorption of vitamin B12 and folic acid
Adverse A risk of lactic acidosis in patients with any of the listed
reactions contraindications; hypoglycemia if taken with a sulfonylurea or in
the presence of alcohol abuse
Precautions Medical history should be checked for contraindications;
hemoglobin and plasma creatinine concentrations should be
checked periodically; should be administered with caution in
patients receiving concomitant cimetidine therapy (may reduce
renal tubular secretion of metformin)
Table 3.1.4: Exclusion Criteria for the Use of Metformin 84
Metformin achieved great success in commercialization. In 1996 Glucophage became the
largest selling oral anti-diabetic agent in the world. Today, around eight million patients
in more than 100 countries worldwide benefit from Glucophage. Metformin stands the
test of time. According to the literature published and patents filed in recent years, it is
still an important research object and has value to be discovered. The following is a
summary of literature search I performed on metformin from 1999 to 2006:
Year ISI Record Counts CNKI Record Counts
1999 187 12
2000 190 21
2001 219 22
84 Metformin, Clifford J. Bailey, Ph.D., M.R.C.Path., and Robert C. Turner, M.D.
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Renal impairment: plasma creatinine values > 1.5 mg per deciliter (132 jimol per liter)
for men and > 1.4 mg per deciliter (124 ptmol per liter) for women
Cardiac or respiratory insufficiency that is likely to cause central hypoxia or reduced
peripheral perfusion
History of lactic acidosis
Severe infection that could lead to decreased tissue perfusion
Liver disease, including alcoholic liver disease, as demonstrated by abnormal
liver-function tests
Alcohol abuse with binge drinking sufficient to cause acute hepatic tonicity
Use of intravenous radiographic contrast agents
2002 323 35
2003 364 78
2004 390 101
2005 452 140
2006 508 165
(Source: Chinese literature source comes from CNKI (http://www.edu.cnki.net), and the
worldwide literature source
(http://portal.. isiknowledge.com).)
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Figure 3.1.7 Search results of metformin from ISI and CNKI
The above chart is a graphic illustration of publications in English ISI database and
Chinese CNKI database.
Below is a time series layout of patent applications related to metformin from different
sources:
Year SIPO Derwent LexisNexis
1999 4 6 5
2000 7 15 12
2001 5 19 22
2002 11 22 36
2003 7 34 55
2004 16 39 39
2005 11 51 41
2006 5 42 29
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(Source: SIPO: the Chinese patent (http://www.sipo.gov.cn), and The Derwent
innovations index (ISI Web of knowledge): US, WO, EP, DE patent
(http://isiklowledge.com).)
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Figure 3.1.8 Summary of search results of metformin-related patents from SIPO, Derwent
and LexisNexis
3.2 PGG Derived from Lagerstroemia Speciosa (Banaba)
3.2.1 Introduction
The reasons of my selecting this case study are in two folds. First, the principal
investigator, Professor Xiaozhuo Chen, is a long-term personal acquaintance who
received education both in China (Tsinghua University) and the US (University of Ohio)
and has intimate knowledge about Chinese herbal medicines and modem chemical
technology and molecular biology. A person of this cross-border background, I believe, is
particularly suited to capitalize on the accumulated knowledge in herbal medicine and
capture value through converting the herbal medicines into food supplements,
nutriceutical medicines (herbal formula) or ethical drugs. Secondly, Professor Chen and
his colleagues overturned a well established and widely published understanding that
corosolic acid, rather than tannic acid PGG as he discovered, is the most potent
therapeutic component in the herb banaba. This case illustrates that the current scientific
understanding of herbal medicines, even for the ones that have been intensively
researched over many decades, is far from complete, a statement that supports the general
hypothesis in this thesis that there is substantial untapped value vested in the Chinese
herbal medicines.
The source of this case study is from both the published articles and private
communications with the innovator and leading researcher of these herbal compounds,
Professor Xiaozhuo Chen, who has given me express permission to disclose the technical
aspects of the innovation and his unpublished data. The technical innovations in this
thesis have been properly filed for patent protection.
Lagerstroemia speciosa (banaba) is a type of tree, more commonly known as banaba,
which grows in Thailand and most of Southeast Asia like the Philippines and Malaysia.
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Banaba is a deciduous, tropical, flowering tree that can grow to 18 m in height, with a 9 to
12 m spread. The large, oblong, dark-green, leathery leaves measure 5 to 10 cm wide by 12
to 30 cm long. The leaves turn an orange-red color in the fall. The flowers are pink to
purple in color, giving way to oval, nut-like fruits. The bark of the tree is thin, mottled, and
peeling.85
7
Figure 3.2.1 Pictures of banaba.86
Banaba is a popular medicine plant in the Philippines, consumed in various forms by
Filipinos for treatment of diabetes and kidney related diseases. For example, banaba tea
has been a traditional health drink in the Philippines since ancient times. It was found to
have therapeutic effects on various ailments such as diabetes, kidney and other urinary
problems. In the countryside, the leaf decoctions were also used for its diuretic and
purgative action and root parts for stomach ailments.
3.2.2 Research history on banaba
Gradually, the popularity of this herbal medicine began to attract scientists worldwide.
After doing numerous in vitro and in vivo studies that consistently confirmed the
anti-diabetic activity of banaba, scientists have identified different components of
banaba to be responsible for its activity. One reason may be that banaba extracts
prepared from banaba leaves from different sources may have different chemical
compositions, leading to different experimental results. In 1940, Garcia F. researched the
hypoglycemic effect of decoction of lagerstroemia speciosa leaf administered orally
(from the J of Philippine Medical Association) 87. In 1993, researchers in Japan
(Murakami et al) isolated corosolic acid from the methanol extract of lagerstroemia
speciosa leaf.88 Their research found that corosolic acid has a significant glucose
transport-stimulating activity at a concentration of 1 LM. Corosolic acid activates the
transport of glucose across cell membranes, resulting in blood sugar reductions. Corosolic
85 www.drugs.conm
86 http://www.stuartxchange.org/Banaba.html
87 On the hypoglycemic effect of decoction of Lagerstroemia speciosa leaves (banaba) administered orally, Garcia F.
( 1940;), J Phil Med Assoc 20:: 395-402.
88 Screening of plant constituents for effect on glucose transport activity in Ehrlich Ascites tumor cells, Murakami C,
Myoga K, Kasai R, Ohtani K, Kurokawa T, Ishibashi S, et al. ( 1993;), Chem Pharm Bull 41::12 2129-31.
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acid (2a-hydroxyursoloic acid) was the first identified as the effective compound of
banaba extract. Corosolic acid also shows a memory effect of blood glucose lowering
even after the treatment is stopped.
In 1996, Kakuda et a189 studied the hypoglycemic effect of lagerstroemia speciosa in
animals and in vitro studies. They found that when genetically diabetic mice (Type II)
were fed a diet containing hot water extract from lagerstroemia speciosa for 5 weeks,
their elevated blood glucose was significantly suppressed. In 1999, Suzuki et al90 found
that when obese diabetic rats were fed a diet containing extract from lagerstroemia
speciosa for 12 weeks, their blood glucose levels were not suppressed, but their body
weights were lowered significantly. In 2001, Liu et al91 found that an extract of
lagerstroemia speciosa leaf has insulin-like glucose uptake - stimulatory and adipocyte
differentiation - inhibitory activities in 3T3-L1 cells. The plant extract may be useful for
prevention and treatment of hyperglycemia and obesity in type II diabetics. In 2002,
William V. Judy et al studied the antidiabetic activity of a standardized extract (from
lagerstroemia speciosa leaf in a dose-dependence study.92 ) In 2004, a group of
researchers found that glucose transporter 4 (GLUT4) translocation from the intracellular
microsomal membrane to the plasma membrane was significantly increased in the muscle
cells of mice treated orally with corosolic acid (p < 0.05). 93 This result is both interesting
and puzzling. The GLUT4 membrane translocation mechanism initiated by corosolic acid
as described must be independent of the insulin receptor mediated signaling pathway
since corosolic acid does not use this pathway for its activity. In 2006, these researchers
found that corosolic acid significantly reduces blood glucose levels and plasma insulin
levels in KK-Ay diabetic mice.94 The mean blood glucose levels of mice at various time
intervals after a single oral administration of corosolic acid 2 mg/kg lowered blood
glucose levels 4 hours after administration (p<0.05). Corosolic acid 10 mg/kg-treated
mice showed a significant decrease in plasma glucose levels 4 and 7 h compared with the
control values (p<0.01).
89 Hypoglycemic effect of extracts from Lagerstroemia speciosa L. leaves in genetically diabetic KK-AY mice, Kakuda T,
Sakane I, Takihara T, Ozaki Y, Takeuchi H, Kuroyanagi M. ( 1996;), Biosci Biotechnol Biochem 60::2 204-8.
90 Antiobesity activity of extracts from Lagerstroemia speciosa L. leaves on female KK-Ay mice, Suzuki Y, Unno T,
Ushitani M, Hayashi K, Kakuda T. ( 1999;), J Nutr Sci Vitaminol 45::6 791-5 (Tokyo).
91 An extract of Lagerstroemia speciosa L. has insulin-like glucose uptake-stimulatory and adipocyte
differentiation-inhibitory activities in 3T3-L1 cells, Liu F, Kim J, Li Y, Liu X, Li J, Chen X. ( 2001;), J Nutr 131::9
2242-7
92 http://www.acu-pro.com/diabetl 
.htm.gb
93 Corosolic acid induces GLUT4 translocation in genetically type 2 diabetic mice, Miura T, Itoh Y, Kaneko T, Ueda N,
Ishida T, Fukushirna M, et al. ( 2004;), Biol Pharm Bull 27::7 1103-5.
94 Antidiabetic effects of corosolic acid in KK-Ay diabetic mice, Miura T, Ueda N, Yamada K, Fukushima M, Ishida T,
Kaneko T, et al. ( 2006;), Biol Pharm Bull 29::3 585-7.
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Figure 3.2.2 Effects of a Single Dose of CA on Blood Glucose in KK-Ay Mice 95
In a different approach, using 3T3-L1 adipocytes as a cell model and a glucose uptake
assay as the functional screening method, Chen (with whom I had continuous
communications) et al showed that the banaba water extract exhibited an insulin-like
glucose transport inducing activity. Penta-o-galloyl-glucopyranose (PGG) was identified
as the most potent gallotannin. A comparison of published data with results obtained for
PGG indicates that PGG has a significantly higher glucose transport stimulatory activity
than lagerstroemin. Chen et al have also shown that PGG exhibits anti-adipogenic
properties in addition to stimulating the glucose uptake in adipocytes. The combination of
glucose uptake and anti-adipogenesis activity is not found in the current insulin mimetic
drugs and may indicate a great therapeutic potential of PGG 96
3.2.3 Development and commercialization of PGG
Turning point of scientific research - identification of PGG
To confirm the effect of corosolic acids, the first step was to isolate them from other
components in the extract, such as tannins, which comprise up to 40% of the extract
material. But a surprise result emerged. When tannins were removed from the material,
glucose transport stimulatory couldn't be found. Then, it was concluded that the glucose
transport activity of the banaba extract was caused by the tannin component, rather than
corosolic acid. This was indeed a turning point of scientific research.
95 Antidiabetic effects of corosolic acid in KK-Ay diabetic mice, Miura T, Ueda N, Yamada K, Fukushima M, Ishida T,
Kaneko T, et al. ( 2006;), Biol Pharm Bull 29::3 585-7.
96 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
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Figure 3.2.3: Absence of glucose transport stimulatory activity of corosolic acid in adipocytes. 97
Although tannins were identified to be responsible for the glucose transport stimulatory
activity of banaba extract, they comprise a wide range of polyphenolic compounds.
Which are the real active components of the extract? Tannic acid, which is also a
constituent of red wine and shows the effects on various health beneficial activities,
provides a further research direction for researchers. The main components of tannic acid
are gallotannins, a sub-class of the tannins usually consisting of a glucose core connected
to many galloyl groups via ester bonds.98 Then, it was confirmed that tannic acid was
much more potent and effective. So the research shifted to focus on tannic acid.
Ga,b,c,d,e =
OH
Gallotannins G = Galloyl Group x = 0, 1, 2,...
Figure 3.2.4 Chemical structures of gallotannins. 99
Further research by Chen et al separated components of tannic acid by HPLC, and
identified penta-o-galloyl-glucopyranose (PGG) as the most potent component of
gallotannins with a glucose uptake assay in 3T3-L1 adipocytes. PGG exist in two anomeric
97 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
98 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
99 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
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forms. The (a-anomer was found to be slightly more active than the P-form in its glucose
transport stimulatory activity, while P-PGG is much more prevalent than a-PGG' 00
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Figure 3.2.5 PGG exist in two anomeric forms. 101
After that, comparison between lagerstroemin and PGG was made. Lagerstroemin was
shown to exhibit glucose transport stimulation at 40gtM with an EC50 of 80pM. In
comparison, a-PGG and 1-PGG exhibit activity at a concentration as low as 10pM with
ECso of 17pLM and 18piM, respectively. In other words, a-PGG and P-PGG are about five
times more potent than lagerstroemin in stimulating glucose transport. Chen's study also
showed that its glucose transport inducing activity is about 54% of that of insulin (22). In
comparison, a-PGG and P-PGG showed about 60-70 % of insulin's glucose transport
inducing activity. Thus, a-PGG and 1-PGG are at least 30% more effective than
lagerstroemin. 102
When PGG was identified, more information about it was obtained and analyzed. It was
found that PGG is widely distributed in many other different plants of different genera,
including euphorbia, acer (maple), quercus (oak), betula (birch), and rhodiola. PGG was
found in different parts of woody medicinal plants including the leaves, roots or rhizomes,
bark, fruits and flowers. Many of these plants have been used clinically to treat diseases.
Some of the PGG-containing plants are edible, either for medical purposes or for human
nutrition, suggesting that PGG is relatively non-toxic to human.
Other researches studying the multiple health beneficial properties of PGG found that it
showed anti-cancer, radical scavenging, anti-virus, anti-diabetes and anti-obesity, as well
as neuronal cell protection activities in cultured cells, animals, and even in humans.
The development of new drugs based on the optimization of small molecular weight
gallotannins, in general, and PGG in particular seems to have a promising outlook. But
PGG has many isomers. Although the molecular weights of all the isomers of PGG are
the same, the chemical properties, such as susceptibility to hydrolysis and
chromatographic behavior, and the biochemical properties, such as the ability to
precipitate protein, are structure-dependent. 10 3 On the other hand, PGG interacts with
different proteins with relatively high affinity to exhibit different bioactivities. Thus, PGG
'10 Distribution, Bioactivities and Therapeutical Potentials of Natural Compound Pentagalloylglucopyranose, by Yulin
Ren, Xiaozhuo Chen, Current Bioactive Compounds, Vol. 3, No. 2. (June 2007), pp. 81-89.
101 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
102 Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa, Chen et al, eCAM Advance Access published
online on March 14, 2007
103 Tannin handbook, www.users.muohio.edu/
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itself has relatively low selectivity for protein targets. This weakness suggests that PGG
has to be chemically modified for each specific activity to enhance the activity in study
and reduce other "interfering" activities. This may also have significant implications on
their potential toxicity properties. Chen's study on modifications and enhancements of
PGG indicates the possibility. The compounds with selected activity can be chemically
generated. T'hese characteristics indicate that PGG is a lead molecule in the biomedical
and biological research of gallotannins and in their development into new therapeutics.
Commercialization
As PGG was found to have great medical potential value, a series of patents filed and a
corporation was established to realize the potential medicinal value, through the control
of patents and licenses related to research findings about banaba extract and further
developed products. Although banaba extract and PGG have multiple beneficial effects,
this firm focuses on their value for diabetes and obesity therapies.
The World Health Organization (WHO) estimates over 180 million people worldwide has
diabetes. This number is likely to double to 360 million by 2030.104 The company plans
to offer a dietary supplement solution derived from banaba extract, for example, banaba
leaf extracts from a Philippine forest. Then a natural agent name C-5, closely related to
the effective agent found in banaba and later a chemically purified to crystals for oral
supplement.
Banaba extract produced by this method has similar glucose uptake profiles to insulin. It
even has an advantage over insulin because insulin cannot be orally administered while
banaba extract and its derivatives can.
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Figure 3.2.6 banaba extract and insulin: Similar Glucose Uptake Profiles'o05
104 Thesis author's private communication with Xiaozhuo Chen.
105 Thesis author's private communication with Xiaozhuo Chen.
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The chemical product C-5 also shows therapy effects on diabetic mice and obese mice
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Figure 3.2.7 C-5 single dose oral administration reduces blood glucose.'0 6
-+- Fed with Water
-- Fed with 0.03mg/g C-5
Figure 3.2.8 Feeding C-5 supplement maintains steady glucose
mice.107
levels in genetically obese
C-5 keeps pre-fat cells in their existing state, but more importantly is that in the presence
of insulin C-5 still prevents fat formation.
106 Thesis author's private communication with Xiaozhuo Chen.
107 Thesis author's private communication with Xiaozhuo Chen.
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Inspiration on drug development from Chinese medical herbs
The development of PGG provides a good example of how to utilize the experience about
medicinal uses of plant to derive molecule products which has the potential to develop
into official drugs. It is a feasible direction for modem development of drugs from past
experiences of medical plants. While Chinese medicine has accumulated experience
about many effective uses of herbs in medical practice, it has great potential value to be
discovered and realized.
Note that, corosolic acid, rather than PGG, has been identified and widely believed as the
effective component for many years. It requires rigorous and persistent research efforts to
challenge the existing discoveries and assumptions, and it may be a long and winding
road before the herb-derived molecules could pass through the FDA regulatory hurdle.
The significance of this case study, however, is the potential feasibility to commercialize
and capture value on earlier raw products such as banaba tannic acid extracts and
modified PGG C-5, not as small molecule drugs, but food supplement and herbal
medicines.
3.3 Grapes, Red Wine and Resveratrol
3.3.1 Introduction
The reasons of my selecting this case study are that, firstly, although resveratrol was first
isolated from grape, the Chinese plant polygonium cuspidatum (hu zhang) has shown to
have 10 times more concentrated resveratrol content; secondly, the published articles in
Chinese journals have proliferated so fast that many clinical trials have already been
conducted to demonstrate the therapeutic benefits of resveratrol; and thirdly, a
Boston-based company co-founded by Dr. Sinclair at Harvard Medical School, Sirtris
Pharmaceuticals, Inc., has swiftly captured the commercial opportunity to convert
resveratrol into an ethical anti-diabetic drug and successfully raised over $100 million
from venture capital and IPO. This is another ongoing case to demonstrate the vast
potential in herbal plants that can be captured once the accumulative empirical
knowledge is coupled with the modem molecular sciences.
The national diet of France includes a lot of high-fat, high-cholesterol foods, such as
butter, cream, meat, and so on, which is suspected to be bad for the heart. Yet the rate of
coronary heart disease mortality in France is lower than those observed in other
industrialized countries with a similar risk factor profile. This well-known fact is called
French Paradox. For hundreds of years, this phenomenon has been studied by many
researchers and it was suggested that the French are somehow protected from
cardiovascular disease because they drink a lot red wine.
As early as the 1920's Dr. Johanna Brandt wrote a book proclaiming that grapes cured her
of cancer. Since then it has been known that there are several beneficial substances in
grapes (wine as well) that assist in lowering cholesterol, reduce the risk of heart disease
and have antioxidant abilities. Further researches focused on the ingredients of red wine,
which led to the discovery of resveratrol. This may be at least partly responsible for the
beneficial effect of red wine. Resveratrol, also known as 3,4',5 trihydroxystilbene and
3,4',5-stilbenetriol, is a compound found largely in the skins of red grapes. It is a naturally
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occurring phytoalexin produced by some plants in response to injury or fungal infection.
Chemical formula of resveratrol is C14HI 20 3 and the molecular weight is 228.25 daltons.
Figure 3.3.1 Grape, red wine and resveratrol 10 8
Physical-chemical properties of resveratrol are as following: 109
Property Information
Physical State Solid, powder
Color Off white
Melting Point ('C) 253-255
Octanol-Water Partition Coefficient (LogP) 3.139+-0.343
pKa (of the most acidic H-donor) 9.14-0.20
Solubility in Water (mol/L) <0.01
Resveratrol is abundant in vitis vinifera, labrusca, and muscadine grapes and exist at a
very high concentration (10 times more concentrated than in grape skin) in the dried roots
and stems of the plant polygonium cuspidatum (also known as "hu zhang" in Chinese,
used in traditional Chinese and Japanese medicine as a circulatory tonic). Other sources
of resveratrol include peanuts and mulberries.
108 http://www.safe:altemativemedicine.co.uk/ReservatrolHealthGrapes.html &
http://www.3dchem.com/molecules.asp?ID=277
109 trans-Resveratrol [501-36-0]: Review of Toxicological Literature, Prepared for Scott Masten, Ph.D., National
Institute of Environmental Health Sciences, by Karen E. Haneke, M.S., Integrated Laboratory Systems, March 2002
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Polygonium cuspidatum
Peanut
Figure 3.3.2 Some plants that contain resveratrol.110
Resveratrol is the parent molecule of a family of polymers called viniferins. Cis- and
trans-resveratrol occur naturally as do their glucosides. The stereoisomer of resveratrol
found in grapes and peanuts is the trans-form. Both cis- and trans-resveratrol are found in
polygonium cuspidatum.
OH
trans-Resver atrol
Bio Site 7/9D2
Figure 3.3.3 Cis- and trans-resveratrol.' 11
110 Pictures are searched from internet.
i 11 http://www.longevinex.com/article.asp?story=Imitations
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3.3.2 Research about resveratrol's beneficial effects
Various test demonstrated that resveratrol may help prevent cardiovascular disease and
cancer. Additionally, a growing number of published reports have appeared both on
Chinese and English-language journals on resveratrol's therapeutic effects on cancer and
various inflammatory diseases. Recent researches of Dr. David Sinclair at Harvard
Medical School and other researchers suggested that resveratrol may even have
life-extending effects.
Life-extending effects
Long time studies on longevity confirm that caloric restriction can extend lifespan in
numerous species. A calorically restricted diet includes all necessary nutrients but has
some 30 percent fewer calories than usual. The diet extends the life span of rodents by 30
to 50 percent, but the prospect of a near-starvation diet is obviously a difficult idea to
market to human populations. Dr. Sinclair and his chief co-author, Dr. Konrad T. Howitz,
of Biomol Research Laboratories in Plymouth Meeting, Pa., claims they have succeeded
in finding a class of drugs that mimic caloric restriction in two standard laboratory
organisms - yeast and fruit flies. It's resveratrol. Other studies show life-extending effects
of resveratrol on other species.
Figure 3.3.4 Life-extending effects of resveratrol on some species.' 12
Dr. Sinclair finds a survival gene that can be "switched on" to become a longevity gene.
The gene increases the production of an enzyme that prolongs the time a living cell has to
112 http://www.longevinex.com/images/resveratrol_experiments_full.jpg
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repair its DNA genetic material. This enzyme is normally produced when the survival of
living cells is threatened by starvation, exposure to germs or bombardment by solar
ultraviolet radiation. No longer would humans have to starve themselves to prolong life.
Scientists involved in the research say that human life spans could be extended by 30
percent if humans respond to the chemicals in the same way as rats and mice do to low
calories. Even someone who started at age 50 to take one of the new chemicals could
expect to gain an extra 10 years of life, said Dr. Leonard Guarente of the Massachusetts
Institute of Technology, one of the pioneers of the new research.
Sir2-like proteins (sirtuins) are a family of NAD+-dependent deacetylases conserved from
Escherichia coli to humans that play important roles in gene silencing, DNA repair, rDNA
recombination and ageing in model organisms. A caloric restricted diet has life-extending
effects in diverse species, suggesting that there is a conserved mechanism for nutrient
regulation of ageing. In budding yeast, extra copies of SIR2 extend lifespan by 30%,
apparently by mimicking caloric restriction. 113 The following figures show the effect of
polyphenolic STACs on sirtuins:
.a
SInRT1
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88% 75%
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113 Sirtuin activators mimic caloric restriction and delay ageing in metazoans, Jason G Wood, Blanka Rogina, Siva
Lavu, Konrad Howitz, Stephen L. Helfand, Marc Tatar & David Sinclair, Nature, August, 2004, VOL 430, 5
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Figure 3.3.5 Effect of polyphenolic STACs on sirtuins (a-g).114
Recently, 18 small molecules from plants were identified that can increase human SIRTI
activity in vitro and in vivo, including resveratrol, butein, and piceatannol. The compound
with the greatest stimulatory activity was resveratrol. 115 Although laboratory tests have
clearly demonstrated that resveratrol may help prevent cardiovascular disease and cancer,
there are several reasons why recommending a population-wide usage would be
premature. First of all, little is known about the absorption and clearance of resveratrol,
the identities of its metabolic products, or its effects on the liver. A study in rats showed
that resveratrol is absorbed in the gut and has a high affinity for the heart and liver.
Secondly, the research on resveratrol has focused on its short-term effects and has been
dominated by in vitro studies on non-human models. Thirdly, its role as a potentiator of
114 Sirtuin activators mimic caloric restriction and delay ageing in metazoans, Jason G Wood, Blanka Rogina, Siva
Lavu, Konrad Howitz, Stephen L. Helfand, Marc Tatar & David Sinclair, Nature, August, 2004, VOL 430, 5
115 Toward a unified theory of caloric restriction and longevity regulation, David A. Sinclair, Available online 11 May
2005, www.sciencedirect.com
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breast carcinomas may significantly limit its use, even for its "proven" benefits. Finally,
its main dietary source is red wine. Not only is its concentration in wine extremely
variable, but recommending increased consumption of red wine to boost resveratrol
intake could certainly do more harm than good. In spite of any beneficial aspects, red
wine and other alcoholic beverages pose health risks that include liver damage and
physical addiction.
3.3.3 Anti-diabetic drug development
As resveratrol has demonstrated so many health beneficial effects, there is great market
potential for related products. It is estimated that there are 200 million people around
world using resveratrol related products, with an annual increase of 50 million. The
market for resveratrol related products will increase quickly in recent years. When I did a
patent search, 185 patents are found in law@LexisNexis database, using resveratrol as the
keyword. As shown on the following pie chart, more than half are related to applications.
type
chem icalsructbre
patents
* process patents
applcation p •ants
Figure 3.3.6 Summary of Resveratrol-related patent search results from LexisNexis
Several methods have been used to extract resveratrol and related compounds from wine
and to isolate the trans- and cis- isomers of resveratrol, including high-performance liquid
chromatography (HPLC), liquid chromatography (LC), gas chromatography (GC), gas
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chromatography-mass spectrometry (GC-MS), and capillary electrophoresis (CE). Most
of the resveratrol-containing supplements which are marketed in the US contain extracts
of the root of polygonium cuspidatum. 116 High-speed counter-current chromatography
-with the solvents chloroform, methanol, and water -was found to be an effective
method for separating resveratrol from polygonum cuspidatum, yielding greater than 98%
purity (as measured by HPLC). It is very interesting to see that most of the technologies
used to extract resveratrol are the same as the fingerprint technologies as I described in
this thesis.
Sirtris Pharmaceuticals, Inc., of which Dr. Sinclair is a cofounder, started clinically
testing its first medicine, a resveratrol-based drug that promises to help keep diabetic
patients' blood sugar under control. Venture capitalists have shown great interest in this
early stage biotech company. According to its website, it has raised over $80 million in
the first two years since the founding of the new company and it successfully IPO's in
early 2007.117
Drug development basing on resveratrol also means great opportunity of operation
between entities in China and outside China. In China, there are a lot of resources of the
material, such as grape and polygonium cuspidatum. Advanced extracting methods
already have been applied in the production. One kilogram of resveratrol only costs RMB
5,000 ($600). Some Chinese researchers have done extensive researches on various
beneficial effects of resveratrol, including clinical trials for cancer and heart failure
treatments. For example, Fei Hongxin et al (2006) studied the effects of resveratrol
against human hepatoma cell line HepG2 cells 11 .Combining the inexpensive and
abundant material resources in China and western molecule research technology, we
could certainly expect a great business opportunity.
116 Resveratrol, http://www.pdrhealth.com
1"7 http://money.cnn.com/2007/01/18/magazines/fortune/Liveforever.fortune/index.htm
118 Depressant effect of resveratrol on human hepatoma cell line HepG2 cells, Fei Hongxin, et al, Heilongjiang Medicine
and Pharmacy, Aug, 2006, Vol 29, No.4, pp 30-31
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4. Discussion
The preceding sections of this thesis has described and defined various aspects of critical
paths to modernize and realize value in Chinese herbal medicine. In the following section,
I propose a few conceptualized value-creation platforms and models.
4.1 Value-Realization Platforms and Models
The following schematic shows a platform that, with the use of scientific technologies for
quality control and material consistency, multiple levels of commercial values may be
created along the trajectory to convert herbs into ethical drugs.
Drug
Foods, Function foods, marketing in Drug
function Chinese medicine China marketing in
foods, herbal world
medicine
Commercialize
Commercialize Commercialize CommercializeCommercialize
Screening Screening Purifica Animal Clinical test
Chinese Extract l of lead L,-tion test =0 and FDA
medicine compound approval
with
clinical
efficacy
Target Target Target Target
market: market: market: market:
market in market in market in global
China and China and China and market
Chinese Chinese Chinese
around around around
world world world
4.2 "Bridge" Opportunities
As discussed at the beginning sections of this thesis about the "bridge" opportunities of
joint drug development from Chinese herbal medicine under the globalization context, a
cross-border virtual platform between China and the US may bring additional value from
three aspects: (1) because the starting point of drug development is often based on
clinically validated Chinese medicines or mixed formulas, such as the case studies have
repeatedly shown, the probability of successful drug development may be increased
relative to the current chemical drug screening processes; (2) a significant amount of
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R&D work and clinical tests may be performed in China, where costs of material and
patient recruiting costs are much lower than those in the US or other western countries,
and (3) potentially
conceptual model.
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Taking the findings in this thesis altogether, it becomes apparent that the herb-derived
drug development pathways could be constructed in a rationally designed fast-track
trajectory. For example, from the empirical efficacy the extract of individual herbs may
be firstly tested on a number of well established animal disease models to generate leads.
Once the leads show evidences of efficacy, the minimally required effective components
may be developed through various technologies such as HPLC, such components then
may be characterized by fingerprint technologies as described in this thesis and tested for
animal toxicity, pharmacokinetics, in vitro and in vivo molecular mechanism and efficacy.
Once herb-derived extracts survive the above development funnel and show overall
promise, they are positioned to undergo further developmental and official regulatory
processes.
5. Conclusion
This thesis supports the hypothesis that significant values are embedded in Chinese
herbal medicine and such value may be created and captured through modernizing
Chinese medicine by current scientific methods and technologies. Both ethical singleton
(chemical) herb-derived drugs and mixed formula herb-derived drugs may be created.
The trend of globalization facilitates and enhances such a value proposition.
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Attachments
Attachment 1: Literature Search Results of CNKI and ISI Relating to the Medical Industry
NewHuman Nove!1 Synthesiza- Experi- Human Formu- NovelPurifica- Manu- Experi Animal Clinical ormu Com- Molecular
year General Extraction tion tion facturing ments Experiments Trials lations pounds Mechanisms
CNKI 2000 43 114 7 199 58 146 24 42 0 18 13
2001 54 140 11 287 81 171 29 40 3 36 32
2002 61 175 18 359 121 281 65 82 5 34 50
2003 59 231 17 395 132 352 78 74 4 48 74
2004 60 262 37 514 172 457 71 108 6 71 134
2005 80 224 31 474 203 467 69 105 5 57 119
2006 37 155 22 270 144 286 37 70 3 48 55
ISI 2000 176 19873 790 434 13623 1328 1263 190 1506 4319
2001 . 228 24355 903 561 16970 1676 1566 289 2123 5273
2002 . 220 22324 832 615 16138 1639 1686 256 2132 5635
2003 . 235 24297 904 652 16889 1684 1918 287 2501 6117
2004 . 252 24632 970 735 18076 1728 1884 344 2645 6872
2005 . 281 25330 993 766 18962 1807 1884 336 2952 7392
2006 . 309 25351 1125 854 20166 1824 1860 349 2997 7931
* About the missing data: the search results are more than 100,000, so are to be ignored
* All of the results of CNKI in 2006 are obviously decreasing; the most likely reason
timely manner. So we can ignore the results of CNKI in 2006.
is that the CNKI database is not updated in a
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Attachment 2: Total Applications for Three Types of Patents Received from China and Abroad" 9
April 1985 - February 2007
Total Invention Utility Model Design
Number % Number % Number % Number %
Sub-total 3429723 100.0% 1126053 100.0% 1315644 100.0% 988026 100.0%
Total Service 1670505 48.7% 853491 75.8% 379828 28.9% 437186 44.2%
Non-service 1759218 51.3% 272562 24.2% 935816 71.1% 550840 55.8%
Sub-total 2805715 100/81.8 586676 100/52.1 1306160 100/99.3 912879 100/92.4
Domestic Service 1072774 38.2% 334803 57.1% 372679 28.5% 365292 40.0%
Non-service 1732941 61.8% 251873 42.9% 933481 71.5% 547587 60.0%
Sub-total 624008 100/18.2 539377 100/47.9 9484 100/0.7 75147 100/7.6
Foreign Service 597731 95.8% 518688 96.2% 7149 75.4% 71894 95.7%
Non-service 26277 4.2% 20689 3.8% 2335 24.6% 3253 4.3%
2007-03-23
119 From: http://www.sipo.gov.cn/sipo English/statistics/szslzlib/200703/t20070323 147084.htm
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Attachment 3: Total Grants for Three Types of Patents Received from China and Overseas 120
April 1985 - February 2007
Total Invention Utility Model Design
Number % Number % Number % Number %
Sub-total 1793786 100.0% 307592 100.0% 860020 100.0% 626174 100.0%
Total Service 843742 47.0% 260384 84.7% 276671 32.2% 306687 49.0%
Non-service 950044 53.0% 47208 15.3% 583349 67.8% 319487 51.0%
Sub-total 1536697 100/85.7 117567 100/38.2 853178 100/99.2 565952 100/90.4
Domestic Service 597769 38.9% 77401 65.8% 271458 31.8% 248910 44.0%
Non-service 938928 61.1% 40166 34.2% 581720 68.2% 317042 56.0%
Sub-total 257089 100/14.3 190025 100/61.8 6842 100/0.8 60222 100/9.6
Foreign Service 245973 95.7% 182983 96.3% 5213 76.2% 57777 95.9%
on-servic 11116 4.3% 7042 3.7% 1629 23.8% 2445 4.1%
2007-03-23
120 From: http://www.sipo.gov.cn/sipo-English/statistics/gnwsqb/200703/t20070323 147089.htm
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Attachment 4: Three Types of Medicinal Patent Applications and Grants 1995-2004121
1995 Application
Grant
1996 Application
Grant
1997 Application
Grant
1998 Application
Grant
1999 Application
Grant
2000 Application
Grant
2001 Application
Grant
2002 Application
Grant
2003 Application
Grant
2004 Application
Grant
Botanical drug
1322
451
1485
559
1527
653
1493
665
1460
640
1815
813
3045
884
2653
970
3698
609
3356
48
121 Statistics on the Patents of Medicinal Invention from 1995 to 2004 in China
-118-
~
Biotech drug
424
198
577
261
649
275
796
338
1136
355
2092
413
1578
434
1673
461
2207
367
1576
120
Drug compound and the method for the production
1455
782
1659
915
1910
911
2127
1008
2074
1206
5064
1351
3447
1104
4546
1068
5598
1056
3739
372
